SECURITIES AND EXCHANGE COMMISSION

                             Washington, DC 20549

                                  -----------

                                   FORM 8-K

                                CURRENT REPORT

                    Pursuant to Section 13 or 15(d) of the

                        Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  September 28, 1998

                        INTEGRA LIFESCIENCES CORPORATION
- -------------------------------------------------------------------------------
            (Exact name of registrant as specified in its charter)

         Delaware                        0-26224              51-0317849
- ----------------------------          -----------            -------------
(State or other jurisdiction          (Commission            (IRS Employer
         of incorporation)            File Number)         Identification No.)

       105 Morgan Lane
       Plainsboro, New Jersey                                  08536
- ----------------------------------------                     ----------
(Address of principal executive offices)                     (Zip Code)

Registrant's telephone number,
including area code:  (609) 275-0500

                                 Not Applicable
- -------------------------------------------------------------------------------
         (Former name or former address, if changed since last report)



ITEM 2.  Acquisition or Disposition of Assets.

On September 28, 1998, Integra LifeSciences Corporation, a Delaware
corporation (the "Company"), acquired all of the outstanding capital stock of
Rystan Company, Inc., a New Jersey corporation ("Rystan"), from GWC Health,
Inc., a New Jersey corporation and the direct parent of Rystan ("GWC"),
pursuant to an Agreement and Plan of Merger (the "Merger Agreement") dated
September 28, 1998 among the Company, RC Acquisition Corporation, a New Jersey
corporation and wholly-owned subsidiary of the Company ("Merger Sub"), GWC and
Rystan. Rystan manufactures and markets a number of medical products,
including its lead product, Panafil(R), an enzymatic debridement agent used to
remove necrotic tissue in wounds, including chronic diabetic foot ulcers.

In accordance with the terms and conditions of the Merger Agreement, Merger
Sub was merged with and into Rystan, with Rystan as the surviving corporation,
resulting in Rystan being a wholly-owned subsidiary of the Company. As
consideration for the merger, the Company issued to GWC 800,000 shares (the
"Shares") of the Company's common stock, par value $.01 per share ("Common
Stock"), and two warrants, each to purchase 150,000 shares of Common Stock
(the "Warrants"). Each of the Warrants may be exercised for shares of Common
Stock at any time after September 28, 1998, for a purchase price per share of
$6.00 and $7.00, respectively, subject to customary antidilution adjustments.
The $6.00 Warrant expires on January 31, 2000, provided that if the average
closing price on the Nasdaq National Market for shares of Common Stock for the
thirty trading days ending on the fifth day immediately preceding the
then-current expiration date is less than $8.00 per share, then the expiration
date shall be extended for one year, but in no event shall be extended beyond
January 31, 2003. The $7.00 Warrant expires on December 31, 2002.

In connection with the transactions contemplated by the Merger Agreement, the
Company entered into a Registration Rights Agreement with GWC pursuant to
which the Company granted to GWC certain registration rights with respect to
the Shares and the shares of Common Stock issued upon exercise of the Warrants
(the "Warrant Shares"). Following the exercise in full of either or both of
the Warrants, GWC may demand the registration of all or part of the Warrant
Shares. GWC may also register all or part of the Shares and the Warrant Shares
on any future registration statement of the Company which registers Common
Stock under the Securities Act of 1933, as amended (the "Act"), for sale to
the public for cash, unless (i) no stockholders of the Company propose to
register or sell their securities in connection with such offering and (ii)
the proceeds to the Company from such offering (after deduction of
underwriting discounts and commissions) are reasonably expected to be less
than $10,000,000. GWC is entitled to two such demand registrations and an
unlimited number of such piggyback registrations until such time as the Shares
and the Warrant Shares may be transferred or sold without registration by
virtue of Rule 144(k) under the Act, as amended, at which time GWC's demand
and piggyback rights terminate.

                                     * * *

                                       2



ITEM 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

Historical financial statements of Rystan and pro forma financial information
are not included with this Report. Such financial information is not required
because Rystan does not qualify as a "significant subsidiary" for purposes of
such disclosure under Rule 1-02(w) of Regulation S-X.

         (c)      Exhibits.

Exhibit Number
(Referenced to
 Item 601 of
 Regulation S-K)           Description of Exhibit

2                          Agreement and Plan of Merger dated September 28,
                           1998 among Integra LifeSciences Corporation, RC
                           Acquisition Corporation, GWC Health, Inc. and Rystan
                           Company, Inc.*

4.1                        Warrant to Purchase 150,000 Shares of Integra
                           LifeSciences Corporation Common Stock at an
                           exercise price of $6.00 per share

4.2                        Warrant to Purchase 150,000 Shares of Integra
                           LifeSciences Corporation Common Stock at an
                           exercise price of $7.00 per share

10.1                       Registration Rights Agreement dated September 28,
                           1998 between Integra LifeSciences Corporation and
                           GWC Health, Inc.

10.2                       Lease dated September 28, 1998 between Rystan
                           Company, Inc. and GWC Health, Inc.

- -----------------------------
*        Integra agrees to furnish supplementally a copy of any omitted 
         schedules or attachments to the Commission upon request.


                                       3



                                  SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act
of 1934, the Company has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                        INTEGRA LIFESCIENCES CORPORATION

Date:  October 13, 1998                 By:   /s/ Stuart M. Essig
                                             ---------------------------------
                                             Stuart M. Essig, President and
                                             Chief Executive Officer

                                       4



                               INDEX OF EXHIBITS

         Exhibit No.                Description of Exhibit

         2                          Agreement and Plan of Merger dated
                                    September 28, 1998 among Integra
                                    LifeSciences Corporation, RC Acquisition
                                    Corporation, GWC Health, Inc. and Rystan
                                    Company, Inc.*

         4.1                        Warrant to Purchase 150,000 Shares of
                                    Integra LifeSciences Corporation Common
                                    Stock at an exercise price of $6.00 per
                                    share

         4.2                        Warrant to Purchase 150,000 Shares of
                                    Integra LifeSciences Corporation Common
                                    Stock at an exercise price of $7.00 per
                                    share

         10.1                       Registration Rights Agreement dated
                                    September 28, 1998 between Integra
                                    LifeSciences Corporation and GWC Health,
                                    Inc.

         10.2                       Lease dated September 28, 1998 between
                                    Rystan Company, Inc. and GWC Health, Inc.

 -----------------------------
*  Integra agrees to furnish supplementally a copy of any omitted schedules or
   attachments to the Commission upon request.

                                       5




                         AGREEMENT AND PLAN OF MERGER

                                    Among

                      INTEGRA LIFESCIENCES CORPORATION,

                         RC ACQUISITION CORPORATION,

                               GWC HEALTH, INC.

                                     and

                             RYSTAN COMPANY, INC.

                        Dated as of September 28, 1998





                              TABLE OF CONTENTS

                                                                     Page

Preamble...............................................................1
Recitals...............................................................1

ARTICLE I  DEFINITIONS

   SECTION 1.01.  Certain Definitions                                  2
   SECTION 1.02.  Other Defined Terms                                  3
   SECTION 1.03.  Accounting Terms                                     5
   SECTION 1.04.  Singular or Plural                                   5

ARTICLE II  THE MERGER

   SECTION 2.01.  The Merger                                           5
   SECTION 2.02.  Merger Consideration                                 5
   SECTION 2.03.  Closing; Effective Time; Delivery                    5
   SECTION 2.04.  Certain Effects of the Merger                        6
   SECTION 2.05.  Conversion of Securities                             6

ARTICLE III  REPRESENTATIONS AND WARRANTIES OF GWC

   SECTION 3.01.  Organization and Qualification; Subsidiaries         7
   SECTION 3.02.  Articles of Incorporation; By-laws                   7

   SECTION 3.03.  Capitalization                                       8
   SECTION 3.04.  Authority; Due Execution                             8
   SECTION 3.05.  No Violations                                        9
   SECTION 3.06.  Compliance with Laws; Permits                        9
   SECTION 3.07.  Financial Statements                                10
   SECTION 3.08.  Absence of Undisclosed Liabilities                  10
   SECTION 3.09.  Absence of Changes or Events                        10
   SECTION 3.10.  Litigation                                          10
   SECTION 3.11.  Material Contracts                                  11
   SECTION 3.12.  Employment and Labor Matters                        11
   SECTION 3.13.  Employee Benefit Plans; ERISA                       11
   SECTION 3.14.  Intellectual Property Rights                        13
   SECTION 3.15.  Tax Matters                                         14
   SECTION 3.16.  Environmental Matters                               14
   SECTION 3.17.  Finders or Brokers                                  16
   SECTION 3.18.  Title to Property                                   16

                                     -i-



                                                                     Page


   SECTION 3.19.  Inventory                                           16
   SECTION 3.20.  Investment Intent                                   16
   SECTION 3.21.  Investment Experience                               17
   SECTION 3.22.  Restricted Securities; Certain Acknowledgments      17
   SECTION 3.23.  Insurance                                           17
   SECTION 3.24.  Customers and Suppliers; Warranties                 18
   SECTION 3.25.  Certain Disclosure                                  18

ARTICLE IV  REPRESENTATIONS AND WARRANTIES OF INTEGRA

   SECTION 4.01.  Organization                                        18
   SECTION 4.02.  Capitalization                                      18
   SECTION 4.03.  Authority; Due Execution                            19
   SECTION 4.04.  Integra Securities                                  20
   SECTION 4.05.  No Violations                                       20
   SECTION 4.06.  SEC Filings                                         20
   SECTION 4.07.  Litigation                                          21
   SECTION 4.08.  Finders or Brokers                                  21
   SECTION 4.09.  Certain Acknowledgments                             21
   SECTION 4.10.  Absence of Changes or Events                        21

ARTICLE V  COVENANTS

   SECTION 5.01.  Further Assurances                                  22
   SECTION 5.02.  Public Announcements                                22
   SECTION 5.03.  Employees and Employee Benefits                     22
   SECTION 5.04.  Certain Restrictive Covenants                       24
   SECTION 5.05.  Costs and Expenses                                  24
   SECTION 5.06.  Consulting Arrangement                              25
   SECTION 5.07.  Packaging                                           25

ARTICLE VI  INDEMNIFICATION

   SECTION 6.01.  Survival                                            25
   SECTION 6.02.  Indemnification by GWC                              25
   SECTION 6.03.  Indemnification by Integra                          26
   SECTION 6.04.  Procedure                                           26
   SECTION 6.05.  Measurement of Damages                              27
   SECTION 6.06.  Investigations                                      27
   SECTION 6.07.  Sole Remedy                                         27

                                     -ii-



                                                                     Page


ARTICLE VII  TAX MATTERS

   SECTION 7.01.  Tax Indemnification by GWC                          27
   SECTION 7.02.  Tax Indemnification by Integra                      27
   SECTION 7.03.  Allocation of Certain Taxes                         28
   SECTION 7.04.  Filing Responsibility                               28
   SECTION 7.05.  Refunds and Carrybacks                              28
   SECTION 7.06.  Cooperation and Exchange of Information             28
   SECTION 7.07.  Closing Date Balance Sheet                          28

ARTICLE VIII  MISCELLANEOUS

   SECTION 8.01.  Amendment and Modification                          29
   SECTION 8.02.  Waiver of Compliance; Consents                      29

   SECTION 8.03.  Tax Opinion                                         29
   SECTION 8.04.  Notices                                             29

   SECTION 8.05.  Assignment; Third Party Beneficiaries               30
   SECTION 8.06.  Governing Law                                       31

   SECTION 8.07.  Severability                                        31
   SECTION 8.08.  Interpretation                                      31
   SECTION 8.09.  Entire Agreement                                    31
   SECTION 8.10.  Counterparts                                        31


EXHIBITS

Exhibit A            -     Form of Registration Rights Agreement
Exhibit B            -     Form of Lease
Exhibit C            -     Forms of Integra Warrants
Exhibit D            -     Form of Secretary's Certificate

                                    -iii-



                                                           Page


SCHEDULES

Section 3.01                                 Organization and Qualification
Section 3.02                                 Articles of Incorporation; Bylaws
Section 3.05                                 No Violations
Section 3.06                                 Compliance with Laws; Permits
Section 3.07                                  Financial Statements
Section 3.08                                 Absence of Undisclosed Liabilities
Section 3.09                                 Absence of Changes or Events
Section 3.10                                 Litigation
Section 3.11                                 Material Contracts
Section 3.12                                 Employment and Labor Matters
Section 3.13                                 Employee Benefit Plans; ERISA
Section 3.14                                 Intellectual Property Rights
Section 3.15                                 Tax Matters
Section 3.18                                 Title to Property
Section 3.19                                 Inventory
Section 3.23                                 Insurance
Section 3.24                                 Customers & Suppliers

                                     -iv-





                         AGREEMENT AND PLAN OF MERGER

         AGREEMENT AND PLAN OF MERGER dated as of September 28, 1998 (this
"Agreement") among Integra LifeSciences Corporation, a Delaware corporation
("Integra"), RC Acquisition Corporation, a New Jersey corporation ("Merger
Sub"), GWC Health, Inc., a New Jersey corporation ("GWC"), and Rystan Company,
Inc., a New Jersey corporation ("Rystan").

         WHEREAS, Integra is the record and beneficial owner of all of the
issued and outstanding shares (the "Merger Sub Shares") of common stock, par
value $.01 per share, of Merger Sub (the "Merger Sub Common Stock");

         WHEREAS, GWC is the record and beneficial owner of all of the issued
and outstanding shares (the "Rystan Shares") of common stock, without nominal
or par value, of Rystan (the "Rystan Common Stock");

         WHEREAS, the parties hereto desire to cause Merger Sub, upon the
terms and subject to the conditions of this Agreement and in accordance with
the Business Corporation Act of the State of New Jersey ("New Jersey Law"), to
merge with and into Rystan (the "Merger");

         WHEREAS, in order to induce GWC to enter into this Agreement, Integra
has agreed to execute in favor of GWC a registration rights agreement in the
form of Exhibit A (the "Registration Rights Agreement");

         WHEREAS, in order to induce Integra to enter into this Agreement, GWC
has agreed to enter into a lease agreement in the form of Exhibit B (the
"Lease"); and

         WHEREAS, for United States federal income tax purposes, the parties
hereto intend that the Merger shall qualify as a reorganization within the
meaning of Section 368(a) of the United States Internal Revenue Code of 1986,
as amended (the "Code").




                                 -2-

         NOW, THEREFORE, in consideration of the foregoing, the mutual
covenants and agreements contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
and intending to be legally bound thereby, the parties hereto agree as
follows:

                                  ARTICLE I

                                 DEFINITIONS

         SECTION 1.01.  Certain Definitions.  For purposes of this Agreement, 
the following terms shall have the following definitions:

         "affiliate" of a specified person means a person who directly, or
indirectly through one or more intermediaries, controls, is controlled by, or
is under common control with, such specified person.

         "control" (including the terms "controlled by" and "under common
control with") means the possession, directly or indirectly or as trustee or
executor, of the power to direct or cause the direction of the management and
policies of a person, whether through the ownership of voting securities, as
trustee or executor, by contract, credit arrangement or otherwise.

         "Disclosure Schedule" means the record to be delivered herewith and
dated the date hereof containing all lists, descriptions, exceptions and other
information and materials as are required to be included therein under this
Agreement.

         "Governmental Authority" means any federal, state or local, foreign
or supra-national government or governmental, regulatory or administrative
authority, agency or commission.

         "GWC's knowledge" means the actual knowledge of any director or 
officer of GWC or Rystan.

         "Integra's knowledge" means the actual knowledge of any director or
officer of Integra or Merger Sub.

         "Integra Material Adverse Effect" means any change in, or effect on,
Integra that is materially adverse to the operations, management, business,
financial condition, results of operations or assets of Integra.

         "person" means an individual, corporation, limited liability company,
partnership, limited partnership, syndicate, person (including, without
limitation, a "person" as defined in Section 13(d)(3) of the Exchange Act),
trust, association or entity or government, political subdivision, agency or
instrumentality of a government.



                                 -3-

         "Property" means the real property located at 47 Center Street,
Little Falls, New Jersey, presently owned by GWC and leased to Rystan.

         "Rystan Material Adverse Effect" means any change in, or effect on,
Rystan that is materially adverse to the operations, management, business,
financial condition, results of operations or assets of Rystan, and shall
include, without limitation, any such change in, or effect on, Rystan that
results in an Integra Loss in an amount in excess of $35,000.

         "subsidiary" of any person means any corporation, partnership, joint
venture or other legal entity of which such person (either above or through or
together with any other subsidiary), owns, directly or indirectly, 50% or more
of the stock or other equity interests, the holders of which are generally
entitled to vote for the election of the board of directors or other governing
body.

         SECTION 1.02. Other Defined Terms. For purposes of this Agreement,
the following capitalized terms shall have the respective meanings given them
in the indicated sections of this Agreement:



Defined Term                                                          Section
- ------------                                                          -------
1997 Balance Sheet................................................  ss. 3.07
1997 Financial Statements.........................................  ss. 3.07
Agreement.........................................................  Preamble
Articles of Incorporation.........................................  ss. 3.02
By-laws...........................................................  ss. 3.02
Carnrick 401(k) Plan............................................... ss. 5.03(b)
CERCLA............................................................  ss. 3.16(d)
Certificate of Merger.............................................. ss. 2.03(a)
Claim.............................................................  ss. 6.04
Closing...........................................................  ss. 2.03(a)
Closing Date......................................................  ss. 2.03(a)
Closing Date Balance Sheet........................................  ss. 7.07(a)
COBRA.............................................................  ss. 3.13(e)
Code..............................................................  Recitals
CSA...............................................................  ss. 3.06(b)
Effective Time....................................................  ss. 2.03(a)
Employee Benefit Plans............................................  ss. 3.13(a)
Environment Law...................................................  ss. 3.16
Environmental Permit..............................................  ss. 3.16
ERISA.............................................................  ss. 3.13(a)
Exchange Act......................................................  ss. 4.06



                                 -4-

Defined Term                                                          Section
- ------------                                                          -------

FDA...............................................................  ss. 3.06(b)
FDCA..............................................................  ss. 3.06(b)
GWC................................................................ Preamble
GWC Indemnified Party.............................................. ss. 6.03(a)
GWC Losses......................................................... ss. 6.03(a)
Hazardous Material................................................. ss. 3.16
Integra............................................................ Preamble
Integra Common Stock............................................... ss. 2.02
Integra Indemnified Party.......................................... ss. 6.02(a)
Integra Losses..................................................... ss. 6.02(a)
Integra Securities................................................. ss. 2.02
Integra Shares..................................................... ss. 2.02
Integra Warrants................................................... ss. 2.02
Intellectual Property Rights....................................... ss. 3.14
Interim Balance Sheet.............................................. ss. 3.07
ISRA............................................................... ss. 3.16
Layer A............................................................ ss. 6.02(c)
Layer B............................................................ ss. 6.02(c)
Lease.............................................................. Recitals
Liens.............................................................. ss. 3.18
Loss............................................................... ss. 6.04
Material Contracts................................................. ss. 3.12
Merger............................................................. Recitals
Merger Sub......................................................... Preamble
Merger Sub Common Stock............................................ Preamble
Merger Sub Shares.................................................. Recitals
New Jersey Law..................................................... Recitals
PBGC............................................................... ss. 3.13(d)
PDMA............................................................... ss. 3.06(b)
Pension Plans...................................................... ss. 3.13(a)
Permitted Liens.................................................... ss. 3.18
Recipients......................................................... ss. 3.13(g)
Registration Rights Agreement...................................... Recitals
Rystan............................................................. Preamble
Rystan Common Stock................................................ Recitals
Rystan Shares...................................................... Recitals
Rystan's Predecessor............................................... ss. 3.16(a)
SEC Filings........................................................ ss. 4.06
Securities Act..................................................... ss. 3.22(a)



                                 -5-

Defined Term                                                          Section
- ------------                                                          -------

Series A Preferred Stock........................................... ss. 4.02
Surviving Corporation.............................................. ss. 2.01
Surviving Corporation Employees.................................... ss. 5.03(a)
Surviving Corporation Welfare Plans................................ ss. 5.03(c)
Tax................................................................ ss. 3.15
Tax Returns........................................................ ss. 3.15
Transaction Costs.................................................. ss. 5.05
Treas. Reg......................................................... ss. 3.15
Welfare Plans...................................................... ss. 3.13(a)

         SECTION 1.03. Accounting Terms. Accounting terms used herein which
are not expressly defined in this Agreement shall have the respective meanings
given to them in accordance with United States generally accepted accounting
principles.

         SECTION 1.04.  Singular or Plural.  Any of the defined terms in this 
Agreement, unless the context otherwise requires, may be used in the singular 
or the plural, depending on the reference.

                                  ARTICLE II

                                  THE MERGER

         SECTION 2.01. The Merger. On the terms and subject to the conditions
set forth herein, and in accordance with the applicable provisions of New
Jersey Law, at the Effective Time, Merger Sub shall be merged with and into
Rystan. As a result of the Merger, the separate corporate existence of Merger
Sub shall cease, and Rystan shall be the surviving corporation of the Merger
(the "Surviving Corporation").

         SECTION 2.02. Merger Consideration. As consideration for the Merger,
Integra shall issue to GWC (a) 800,000 shares (the "Integra Shares") of common
stock, par value $.01 per share, of Integra (the "Integra Common Stock") and
(b) warrants to purchase an aggregate of 300,000 shares of Integra Common
Stock in the forms of Exhibit C (the "Integra Warrants"). The Integra Shares
and the Integra Warrants collectively are referred to herein as the "Integra
Securities."

         SECTION 2.03.  Closing; Effective Time; Delivery.

                  (a) Closing; Effective Time. The closing of the transactions
         contemplated by this Agreement (the "Closing") will be held at 12:00
         p.m., New York City time, on the date of signing of this Agreement
         (the "Closing Date") at the offices of Cahill Gordon & Reindel, 80
         Pine Street, New York, New York. On the Closing Date, the parties
         shall file a certificate of merger (the "Certificate of Merger") with
         the Secretary of State of the State of New Jersey, in such form as is
         required by, and executed in accordance with, the relevant provisions
         of New Jersey Law. The Merger shall be effective at the time at which
         the Certificate of Merger is filed with the Secretary of State of the
         State of New Jersey (the "Effective Time").




                                 -6-

                  (b) Delivery. At the Closing, (i) GWC shall deliver to
         Integra (x) (1) one or more certificates representing all of the
         Rystan Shares duly endorsed or accompanied by stock powers duly
         endorsed in blank or (2) an affidavit of loss and indemnity with
         respect to the Rystan Shares, (y) the Registration Rights Agreement
         duly executed and (z) the Lease duly executed and (ii) Integra shall
         deliver to GWC (w) (1) one or more certificates representing the
         Integra Shares registered in the name of GWC or (2) a letter to
         Integra's transfer agent irrevocably instructing such transfer agent
         to issue one or more certificates representing all of the Integra
         Shares registered in the name of GWC, (x) the Integra Warrants duly
         executed, (y) the Registration Rights Agreement duly executed and (z)
         the Lease duly executed. In addition, each of Integra, Merger Sub,
         GWC and Rystan shall deliver at the Closing a duly executed
         certificate of its Secretary in the form of Exhibit D.

                  (c) The parties hereto expressly acknowledge that damages
         alone may be an inadequate remedy for any breach or violation of any
         of the provisions of this Section 2.03, and that each party, in
         addition to all other remedies under this Agreement, shall be
         entitled to seek injunctive relief, including specific performance,
         with respect to any such breach or violation, in any court of
         competent jurisdiction.

         SECTION 2.04.  Certain Effects of the Merger.

                  (a) At the Effective Time, the effect of the Merger shall be
         as provided in the applicable provisions of New Jersey Law.

                  (b) At the Effective Time, the Articles of Incorporation of
         the Surviving Corporation shall be the Articles of Incorporation of
         Merger Sub as in effect immediately prior to the Effective Time until
         thereafter amended as provided by law.

                  (c) At the Effective Time, the By-laws of Surviving
         Corporation shall be the By-laws of Merger Sub as in effect
         immediately prior to the Effective Time until thereafter amended as
         provided by law.

                  (d) The directors and officers of Merger Sub immediately
         prior to the Effective Time shall be the directors and officers of
         the Surviving Corporation, each to hold office in accordance with the
         Articles of Incorporation and By-laws of the Surviving Corporation,
         until their respective successors are duly elected or appointed and
         qualified.

         SECTION 2.05.  Conversion of Securities.

                  (a) Merger Sub Shares. At the Effective Time, by virtue of
         the Merger and without any action on the part of the parties hereto,
         each Merger Sub Share shall be converted into and become one fully
         paid and non-assessable share of common stock, par value $.01 per
         share, of the Surviving Corporation.



                                 -7-

                  (b) Rystan Shares. At the Effective Time, by virtue of the
         Merger and without any action on the part of the parties hereto, the
         Rystan Shares shall be converted into the right to receive the
         Integra Securities and shall be canceled and retired and shall cease
         to exist, and thereafter GWC shall have no rights with respect to the
         Rystan Shares except the right to receive the Integra Securities.
         Upon delivery by GWC of the certificate or certificates representing
         the Rystan Shares to Integra at the Closing as provided in Section
         2.03(b), Integra shall forthwith cancel such certificate or
         certificates.

                                 ARTICLE III

                    REPRESENTATIONS AND WARRANTIES OF GWC

                  GWC hereby represents and warrants to Integra that:

         SECTION 3.01.  Organization and Qualification; Subsidiaries.

                  (a) Each of GWC and Rystan is a corporation duly
         incorporated, validly existing and in good standing under the laws of
         the State of New Jersey. Rystan has the requisite corporate power and
         authority to own, lease and operate its assets and properties, to
         perform its obligations, and to carry on its business as it is now
         being conducted, except where the lack of such power or authority has
         not had and is not reasonably likely to have, individually or in the
         aggregate, a Rystan Material Adverse Effect. Rystan is duly qualified
         or licensed as a foreign corporation to do business, and is in good
         standing, in each jurisdiction where the character of the assets and
         properties owned, leased or operated by it or the nature of its
         activities makes such qualification or licensing necessary, except
         for such failures to be so qualified or licensed and in good standing
         that have not had and are not reasonably likely to have, individually
         or in the aggregate, a Rystan Material Adverse Effect.

                  (b) Except as disclosed in Section 3.01 of the Disclosure
         Schedule, Rystan does not directly or indirectly own any equity or
         similar interest in, or any interest convertible into or exchangeable
         or exercisable for any equity or similar interest in, any
         corporation, partnership, limited liability company, joint venture or
         other business association or entity.

         SECTION 3.02. Articles of Incorporation; By-laws. Section 3.02 of the
Disclosure Schedule sets forth complete and correct copies of the Articles or
Certificate of Incorporation, as amended to date (the "Articles of
Incorporation"), certified as to a recent date by the Secretary of State of
the State of New Jersey, and the By-laws, as amended to date (the "By-laws"),
of Rystan. Such Articles of Incorporation and By-laws are in full force and
effect on the date hereof. Except as disclosed in Section 3.02 of the
Disclosure Schedule, as of the date



                                 -8-

hereof, Rystan is not in material violation of any provision of its Articles 
of Incorporation or By-laws.

         SECTION 3.03. Capitalization. The authorized capital stock of Rystan
consists of 2,500 shares of Rystan Common Stock. As of the date of this
Agreement, there are 2,500 shares of Rystan Common Stock issued and
outstanding. There are no existing options, warrants, calls, subscriptions, or
other similar rights, commitments or agreements obligating GWC or Rystan to
issue, transfer or sell any shares of capital stock of Rystan or any other
securities convertible into or evidencing the right to subscribe for any
shares of capital stock of Rystan. There are no outstanding stock appreciation
rights with respect to any Rystan Common Stock. All outstanding shares of
Rystan Common Stock are duly authorized and validly issued, fully paid and
non-assessable. GWC directly owns all of the outstanding shares of Rystan
Common Stock (i.e., the Rystan Shares) free and clear of any Liens.

         SECTION 3.04.  Authority; Due Execution.

                  (a) GWC has all necessary corporate power and authority to
         execute and deliver this Agreement, the Registration Rights Agreement
         and the Lease and to consummate the transactions contemplated hereby
         and thereby. The execution and delivery of this Agreement, the
         Registration Rights Agreement and the Lease by GWC and the
         consummation by GWC of the transactions contemplated hereby and
         thereby have been duly and validly authorized by all necessary
         corporate action and no other proceedings on the part of GWC are
         necessary to authorize this Agreement, the Registration Rights
         Agreement or the Lease or consummate the transactions contemplated
         hereby and thereby. Each of this Agreement, the Registration Rights
         Agreement and the Lease has been duly and validly executed and
         delivered by GWC and, assuming the due authorization, execution and
         delivery hereof and thereof by the other parties thereto, constitutes
         a valid and binding obligation of GWC, enforceable against GWC in
         accordance with its terms, subject to bankruptcy, insolvency,
         fraudulent transfer, reorganization, moratorium or other laws of
         general applicability relating to or affecting creditors' rights and
         to general equity principles.

                  (b) Rystan has all necessary corporate and shareholder power
         and authority to execute and deliver this Agreement and to consummate
         the transactions contemplated hereby. The execution and delivery of
         this Agreement by Rystan and the consummation by Rystan of the
         transactions contemplated hereby have been duly and validly
         authorized by all necessary corporate and shareholder action and no
         other proceedings on the part of Rystan or its shareholder are
         necessary to authorize this Agreement or consummate the transactions
         contemplated hereby. This Agreement has been duly and validly
         executed and delivered by Rystan and, assuming the due authorization,
         execution and delivery hereof by the other parties thereto,
         constitutes a valid and binding obligation of Rystan, enforceable
         against Rystan in accordance with its terms, subject to bankruptcy,
         insolvency, fraudulent transfer, reorganization,



                                 -9-

         moratorium or other laws of general applicability relating to or 
         affecting creditors' rights and to general equity principles.

         SECTION 3.05. No Violations. Except as disclosed in Section 3.05 of
the Disclosure Schedule, no filing with, notification to or permit,
authorization, consent or approval of, any Governmental Authority is necessary
on the part of GWC or Rystan for the consummation by GWC and Rystan of the
transactions contemplated hereby, except for filings, notifications, permits,
authorizations, consents or approvals, the failure of which to make, receive
or obtain are not reasonably likely to, individually or in the aggregate,
impair GWC's or Rystan's ability to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement, the Registration Rights
Agreement and the Lease and the consummation of the transactions contemplated
hereby and thereby do not (i) conflict with or breach any provision of the
Articles of Incorporation or By-laws of GWC or Rystan, (ii) violate any order,
writ, injunction, decree, statute, rule or regulation applicable to GWC,
Rystan or any of Rystan's assets, (iii) result in, require or permit the
creation or imposition of any Lien upon or with respect to the Rystan Shares,
Rystan or its assets, or (iv) violate, breach or constitute a default under
any of the terms, conditions or provisions of any agreement or other
instrument to which Rystan is a party, excluding such violations, breaches or
defaults that, individually or in the aggregate, are not reasonably likely to
impair GWC's or Rystan's ability to consummate the transactions contemplated
hereby or that have not had and are not reasonably likely to have,
individually or in the aggregate, a Rystan Material Adverse Effect.

         SECTION 3.06.  Compliance with Laws; Permits.

                  (a) Except as disclosed in Section 3.06 of the Disclosure
         Schedule: (i) Rystan is not in violation of any statute, law,
         ordinance, regulation, rule or order of any Governmental Authority or
         any judgment, decree or order of any court, applicable to its
         business or operations, except for such violations that have not had
         and are not reasonably likely to have, individually or in the
         aggregate, a Rystan Material Adverse Effect; (ii) Rystan has not
         received any written notice, order or other written communication
         from any Governmental Authority of any alleged, actual or potential
         violation of any such law, ordinance, regulation, rule or order,
         except with respect to such violations as have not had and are not
         reasonably likely to have, individually or in the aggregate, a Rystan
         Material Adverse Effect; and (iii) Rystan has all permits, licenses
         and franchises from Governmental Authorities required to conduct its
         business as now being conducted and no proceeding is pending or, to
         GWC's knowledge, threatened by any person to revoke or deny the
         renewal of any such permit, license or franchise, except in each case
         for such permits, licenses and franchises the absence of which has
         not had and is not reasonably likely to have, individually or in the
         aggregate, a Rystan Material Adverse Effect.

                  (b) As to each product subject to the jurisdiction of the
         Food and Drug Administration under the Federal Food, Drug and
         Cosmetic Act ("FDCA") or the Prescription Drug Marketing Act ("PDMA")
         and the jurisdiction of the Drug Enforcement Agency under the
         Comprehensive Drug Abuse Prevention and Control




                                 -10-

         Act of 1970 ("CSA") which is manufactured, tested, distributed, held
         and/or marketed by Rystan, such product is being manufactured, held and
         distributed in compliance in all material respects with all applicable
         requirements under the FDCA, PDMA and the CSA including, but not
         limited to, those relating to investigational use, premarket clearance,
         good manufacturing practices, labeling, promotion and advertising,
         record keeping, filing of reports and security.

         SECTION 3.07. Financial Statements. Section 3.07 of the Disclosure
Schedule contains (i) the audited financial statements of Rystan at and for
the year ended December 31, 1997 (the "1997 Financial Statements" and the
December 31, 1997 balance sheet included therein, the "1997 Balance Sheet")
and (ii) the audited balance sheet of Rystan as of May 31, 1998 (the "Interim
Balance Sheet"). The 1997 Financial Statements and the Interim Balance Sheet
were prepared in accordance with United States generally accepted accounting
principles consistently applied (except as may be indicated therein), and each
fairly presents in all material respects the financial position, results of
operations and cash flows of Rystan at the respective dates thereof and for
the respective periods indicated therein in accordance with United States
generally accepted accounting principles consistently applied (except as may
be indicated therein).

         SECTION 3.08. Absence of Undisclosed Liabilities. Except as set forth
in the Interim Balance Sheet or disclosed in Section 3.08 of the Disclosure
Schedule, Rystan has no liability or obligation in an amount in excess of
$20,000, except for liabilities and obligations (i) incurred in the ordinary
course of business consistent with past practice since May 31, 1998 or (ii)
incurred pursuant to or in connection with this Agreement.

         SECTION 3.09. Absence of Changes or Events. Except as disclosed in
Section 3.09 of the Disclosure Schedule, or as otherwise contemplated by this
Agreement, since December 31, 1997, Rystan has not:

                  (a) authorized for issuance, issued, sold, delivered or
         granted any options, warrants, calls, subscriptions or other rights
         for, or otherwise agreed or committed to issue, sell or deliver, or
         made any distributions with respect to, any shares of any class of
         its capital stock or any securities convertible into or exchangeable
         or exercisable for shares of any class of its capital stock;

                  (b) made any payment to an affiliate;

                  (c) changed its accounting methods, principles or practices,
         except as required by GAAP, or changed any of the assumptions
         underlying, or methods of calculating, any bad debt, contingency or
         other reserve;

                  (d) taken any other actions except in the ordinary course of
         business consistent with past practice; or

                  (e) taken any other action or suffered any other change that
         has had or is reasonably likely to have, individually or in the
         aggregate, a Rystan Material Adverse Effect.

         SECTION 3.10. Litigation. Except as disclosed in Section 3.10 of the
Disclosure Schedule, there are no claims, actions, proceedings or
investigations pending or, to GWC's



                                 -11-

knowledge, threatened against Rystan or its directors or officers in their
capacities as such or any asset of Rystan before any court, arbitrator or
Governmental Authority. No claim, proceeding, action of investigation disclosed
in Section 3.10 has had or is reasonably likely to have, individually or in the
aggregate, a Rystan Material Adverse Effect. As of the date hereof, neither
Rystan nor any asset of Rystan is subject to any order, writ, judgment,
injunction, decree, determination or award that has had or is reasonably likely
to have, individually or in the aggregate, a Rystan Material Effect.

         SECTION 3.11. Material Contracts. Except as disclosed in Section 3.11
of the Disclosure Schedule, Rystan is not a party to any existing contract,
agreement or instrument of any type (a) involving amounts in excess of $20,000
or (b) with any affiliate of Rystan (collectively, the "Material Contracts").
With such exceptions as have not had and are not reasonably likely to have,
individually or in the aggregate, a Rystan Material Adverse Effect, (i) each
Material Contract is valid, binding and in full force and effect and is
enforceable by Rystan in accordance with its terms and (ii) Rystan has
performed all material obligations required to be performed by it to date
under each Material Contract.

         SECTION 3.12. Employment and Labor Matters. Rystan is not a party to
any union contract or other collective bargaining agreement. Rystan is in
compliance with all applicable laws respecting employment and employment
practices, terms and conditions of employment and wages and hours, except for
those failures to comply that have not had and are not reasonably likely to
have, individually or in the aggregate, a Rystan Material Adverse Effect.
There is no labor strike, slowdown or stoppage pending or, to GWC's knowledge,
threatened against Rystan. Except as disclosed in Sections 3.11 and 3.12 of
the Disclosure Schedule, Rystan is not a party to any employment, management
services, or consultation contract or agreement (other than unwritten
employment agreements terminable at will without payment of any contractual
severance or other amount). Except as disclosed in Section 3.12 of the
Disclosure Schedule, to GWC's knowledge, none of Rystan's employees is a party
to, or is otherwise bound by, any agreement or arrangement with any person
other than Rystan (including, without limitation, any confidentiality,
non-competition or proprietary rights agreement) that in any way limits or
adversely affects the performance of his or her duties, his or her freedom to
engage in the business conducted by Rystan or the ability of Rystan to conduct
its business.

         SECTION 3.13.  Employee Benefit Plans; ERISA.

                  (a) Except as disclosed in Section 3.13 of the Disclosure
         Schedule, there are no "employee pension benefit plans" as defined in
         Section 3(2) of the Employee Retirement Income Security Act of 1974,
         as amended ("ERISA") ("Pension Plans"), "welfare benefit plans" as
         defined in Section 3(1) of ERISA ("Welfare Plans"), stock option or
         other stock-based plans, deferred compensation plans or other plans
         or arrangements to provide benefits to employees (or former
         employees) of Rystan maintained or contributed to by Rystan
         (collectively, the "Employee Benefit Plans").

                  (b) Except where the failure to comply has not had and is
         not reasonably likely to have, individually or in the aggregate, a
         Rystan Material Adverse Effect:



                                 -12-

         (i) Rystan, with respect to its operation of the Pension Plans
         and Welfare Plans, and each of the Pension Plans and Welfare
         Plans are in compliance in both form and operation with the
         applicable provisions of ERISA, the Code and other applicable
         laws; and (ii) all contributions to, and payments from, the
         Employee Benefit Plans which are required to have been made in
         accordance with the Employee Benefit Plans have been timely
         made.

                  (c) With respect to any Pension Plan maintained by Rystan or
         any of its controlled group affiliates (under Section 414 of the
         Code) which is subject to Section 412 of the Code or Section 302 of
         ERISA, (i) all contributions required to be made under Section 302 of
         ERISA and Section 412 of the Code have been timely made, (ii) there
         has been no application for or waiver of the minimum funding
         standards imposed by Section 412 of the Code and (iii) no such plan
         has incurred an "accumulated funding deficiency" within the meaning
         of Section 412(a) of the Code as of the end of the most recently
         completed plan year, except where such failures in (i), (ii) and
         (iii) above have not had and are not reasonably likely to have,
         individually or in the aggregate, a Rystan Material Adverse Effect.

                  (d) Except as disclosed in Section 3.13 of the Disclosure
         Schedule, with respect to any Pension Plan maintained by Rystan or
         any of its controlled group affiliates (under Section 414 of the
         Code) which is subject to Title IV of ERISA, (i) within the five-year
         period ending on the date hereof, no such plan has been terminated or
         has been the subject of a "reportable event" (as defined in Section
         4043 of ERISA and the regulations thereunder) for which the 30-day
         notice requirement has not been waived by the Pension Benefit
         Guaranty Corporation ("PBGC") and (ii) none of Rystan or any of its
         controlled group affiliates (under Section 414 of the Code) has
         incurred any unpaid liability under Title IV of ERISA, except where
         such event in (i) and (ii) above has not had and is not reasonably
         likely to have, individually or in the aggregate, a Rystan Material
         Adverse Effect.

                  (e) None of the Welfare Plans maintained by Rystan nor any
         binding contract of Rystan provides for continuing welfare benefits
         or coverage for any participant or any beneficiary of a participant
         following termination of employment, except as may be required under
         the Consolidated Omnibus Budget Reconciliation Act of 1985, as
         amended ("COBRA"), or except at the expense of the participant or the
         participant's beneficiary.

                  (f) None of Rystan or any of its controlled group affiliates
         (under Section 414 of the Code) contributes to or has any material
         liability, including potential withdrawal liability, with respect to
         any "multiemployer plan" (as defined in Section 3(37) of ERISA)
         covering employees of Rystan.

                  (g) Except as provided in Section 3.13 of the Disclosure
         Schedule, the transactions contemplated hereby will not, separately
         or together, (i) entitle any employee, officer, or director of Rystan
         to severance pay or any other payment or (ii)



                                 -13-

         accelerate the time of payment or vesting of, or increase the
         amount of, compensation due to any such employee, officer or
         director. No payment made by Rystan to any officer, director,
         employee or agent of Rystan (in such capacity, "Recipients")
         pursuant to any employment contract, severance agreement or
         other arrangement will be non-deductible to Rystan or the
         Surviving Corporation because of the applicability of the
         "golden parachute" provisions of Section 280G and 4999 of the
         Code, nor will Rystan or the Surviving Corporation be required
         to "gross up" or otherwise compensate any Recipient because of
         the imposition of any excise tax (including any interest or
         penalties related thereto) on the Recipient as a result of
         Sections 280G and 4999 of the Code.

                  (h) Complete and correct copies of the following documents
         have been delivered or made available by Rystan to Integra: (i) all
         current plan documents and insurance contracts (if any), and
         amendments thereto, with respect to each of the Employee Benefit
         Plans; (ii) for each of the most recently ended three plan years, all
         available IRS Form 5500 series forms (and any financial statement and
         other schedules attached thereto) with respect to any Employee
         Benefit Plan; (iii) the most recent IRS determination letter for each
         Pension Plan; and (iv) all current summary plan descriptions and
         subsequent summaries of material modifications with respect to each
         of the Employee Benefit Plans subject to ERISA and any similar
         documents for any other Employee Benefit Plan.

         SECTION 3.14. Intellectual Property Rights. Section 3.14 of the
Disclosure Schedule contains a list of all trade names, trademarks and service
marks, and applications for the foregoing, owned or possessed by Rystan.
Except as disclosed in Section 3.14 of the Disclosure Schedule: (i) Rystan is
the sole owner of or has the right to use all Intellectual Property Rights
currently used by Rystan and in the manner so used, free and clear of any and
all Liens; (ii) such Intellectual Property Rights are sufficient for the
conduct of the business of Rystan as it is presently conducted; and (iii) the
rights of Rystan in and to all of its Intellectual Property Rights will not be
limited or otherwise affected by virtue of the transactions contemplated
hereby. No material rights or licenses to use Intellectual Property Rights
have been granted or acquired by Rystan except those disclosed in Section 3.14
of the Disclosure Schedule. Except as disclosed in Section 3.14 of the
Disclosure Schedule, Rystan has not received written notice or, to GWC's
knowledge, other notice of any claims or assertions made by others that Rystan
has infringed Intellectual Property Rights of others by the sale of products
or any other activity in the preceding five-year period. Except as disclosed
in Section 3.14 of the Disclosure Schedule, Rystan has no knowledge of any
infringement of its Intellectual Property Rights by others that has had or is
reasonably likely to have, individually or in the aggregate, a Rystan Material
Adverse Effect. "Intellectual Property Rights" means and includes rights to
use patents, trademarks, service marks, trade names, copyrights, and currently
pending applications for any thereof, and any inventions (whether or not
patentable), processes, trade secrets, know-how, secrecy or confidentiality
agreements, consulting agreements, software licenses, and any and all
information related to any of the foregoing.




                                 -14-

         SECTION 3.15.  Tax Matters.

                  (a) Except as disclosed in Section 3.15 of the Disclosure
         Schedule: (i) all franchise, income and all other Tax returns,
         information statements and reports and other filings (Tax returns,
         information statements, reports and other filings are hereinafter
         collectively referred to as "Tax Returns") required to be filed for
         any period or portion thereof at or before the Effective Time, taking
         into account any extension of time to file granted to or obtained on
         behalf of Rystan, have been prepared and timely filed by or on behalf
         of Rystan with the appropriate Governmental Authorities and all such
         returns were complete and correct in all material respects; (ii) all
         Taxes of Rystan in respect of any taxable period (or portion thereof)
         ending at or prior to the Effective Time which are due have been paid
         in full to the proper authorities or fully accrued for on the
         financial statements of Rystan, other than such Taxes as are being
         contested in good faith by appropriate proceedings and are adequately
         reserved for in accordance with United States generally accepted
         accounting principles; (iii) no extension of the period for
         assessment or collection of any Tax is currently in effect and no
         extension of time within which to file any Tax Return has been
         requested, which Tax Return has not since been filed; and (iv) there
         are no Tax sharing agreements or arrangements under which Rystan will
         have any obligation or liability at or after the Effective Time.

                  (b) Except as disclosed in Section 3.15 of the Disclosure
         Schedule: (i) no examination of Rystan is pending or, to GWC's
         knowledge, threatened for any material amount of Tax by any
         Governmental Authority, and no Tax liens have been filed with respect
         to any of the assets of Rystan, except for property taxes which have
         accrued but are not yet due and payable; (ii) Rystan has made timely
         payments of the Taxes required to be deducted and withheld from the
         wages it paid to its employees and from amounts it paid to any other
         third parties; (iii) Rystan has not made an election under Section
         341(f) of the Code; and (iv) Rystan has not agreed, and is not
         required, to include in income any adjustment pursuant to Section
         481(a) of the Code.

                  "Tax" means (i) all federal, state, local or foreign taxes,
                  charges, fees, imposts, levies or other assessments,
                  including, without limitation, all net income, alternative
                  minimum, gross receipts, capital, sales, use, ad valorem,
                  value added, transfer, franchise, profits, inventory,
                  capital stock, license, withholding, payroll, employment,
                  social security, unemployment, excise, severance, stamp,
                  occupation, property and estimated taxes, customs duties,
                  fees, assessments and charges of any kind whatsoever, (ii)
                  all interest, penalties, fines, additions to tax or other
                  additional amounts imposed by any Governmental Authority in
                  connection with any item described in clause (i), and (iii)
                  all transferee, successor, joint and several or contractual
                  liability (including, without limitation, liability pursuant
                  to United States Treasury Regulation ("Treas. Reg.") ss.
                  1.1502-6 (or any comparable state, local or foreign
                  provisions)) in respect of any items described in clause (i)
                  or (ii) above.

         SECTION 3.16.  Environmental Matters.



                                 -15-

                  (a) Rystan possesses all Environmental Permits required
         under applicable Environmental Laws to conduct its business as
         presently conducted, and is and has at all times been in compliance
         with the terms and conditions of such Environmental Permits.

                  (b) Rystan is in compliance and, within the period of all
         applicable statutes of limitation, each of Rystan and Rystan Company,
         Inc., a New York corporation and the predecessor to Rystan ("Rystan's
         Predecessor") has complied with all applicable Environmental Laws and
         has not received notice of any liability under any Environmental Law.

                  (c) There are no civil, criminal, or administrative actions,
         suits, demands, claims, hearings, notices of violation,
         investigations, notices or demand letters, or requests for
         information pending under any Environmental Law against Rystan or
         Rystan's Predecessor.

                  (d) Neither the Property nor any other property or facility
         presently or formerly owned, operated or leased by Rystan or Rystan's
         Predecessor is listed or proposed for listing on the National
         Priorities List or the Comprehensive Environmental Response,
         Compensation and Liability Information System, both promulgated under
         the Comprehensive Environmental Response, Compensation and Liability
         Act of 1980, as amended ("CERCLA"), or on any comparable list
         established under any

         Environmental Law.

                  (e) There was no disposal, spill, discharge, or release of
         any Hazardous Material on, at, or under the Property or any other
         property or facility presently or formerly owned, leased or operated
         by Rystan or Rystan's Predecessor (x) at any time during which Rystan
         or Rystan's Predecessor owned, leased or operated the Property or
         other such property or facility or (y) in connection with
         manufacturing, packaging or other activities related to the business
         of Rystan or Rystan's Predecessor performed by, for or on behalf of
         Rystan or Rystan's Predecessor, in either case that could require
         response, corrective or other action under any Environmental Law by
         the Surviving Corporation, Rystan or Rystan's Predecessor

                  (f) There was no disposal, spill, discharge, or release of
         any Hazardous Material on, at, or under the Property or any other
         property presently or formerly owned, leased, or operated by Rystan
         or Rystan's Predecessor (x) at any time during which neither Rystan
         nor Rystan's Predecessor owned, leased or operated the Property or
         other such property or facility or (y) other than in connection with
         manufacturing, packaging or other activities related to the business
         of Rystan or Rystan's Predecessor performed by, for or on behalf of
         Rystan or Rystan's Predecessor, in either case that could require
         response, corrective or other action under any Environmental Law by
         the Surviving Corporation, Rystan or Rystan's Predecessor.



                                 -16-


                  (g) This Section 3.16 constitutes GWC's sole representation
         with respect to any Environmental Law, Environmental Permit or
         Hazardous Material.

         "Environmental Law" means CERCLA, the Resource Conservation and
Recovery Act of 1976, as amended, the New Jersey Industrial Site Recovery Act
("ISRA"), the New Jersey Spill Compensation and Control Act, and any other
applicable federal, state, local, or foreign statute, rule, regulation, order,
decree or judgment relating to pollution or protection of the environment,
including, without limitation, release or threatened release of Hazardous
Material.

         "Environmental Permit" means any permit, license, approval, or other
authorization by a federal, state, local, or foreign government or regulatory
entity pursuant to any Environmental Law.

         "Hazardous Material" means any pollutant, contaminate, or hazardous
or toxic waste or substance regulated by any applicable Environmental Law.

         SECTION 3.17. Finders or Brokers. Neither GWC nor any of its
affiliates has employed any investment banker, broker, finder or intermediary
in connection with the transactions contemplated hereby who may reasonably be
expected to be entitled to a fee or any commission, directly or indirectly,
from any such person.

         SECTION 3.18. Title to Property. Section 3.18 of the Disclosure
Schedule lists each interest in real property leased by Rystan, including a
listing of all leases and other agreements under which any such real property
is held. Rystan does not own or have any other interest in real property other
than pursuant to such leases. Rystan has good and marketable title to all of
its (i) leasehold interests listed in Section 3.18 of the Disclosure Schedule
and (ii) personal property, including all equipment and leasehold improvements
located at Rystan's principal offices, all of which are free and clear of any
and all liens, pledges, security interests or other encumbrances of every
kind, nature and description whatsoever ("Liens"), except (i) the Liens set
forth in Section 3.18 of the Disclosure Schedule and (ii) Liens that are
matters of public record or which do not, individually or in the aggregate,
materially impair the value, marketability or operations of the interest or
property to which they relate in the operation of Rystan as currently
conducted ((i) and (ii) collectively, "Permitted Liens").

         SECTION 3.19. Inventory. Except as disclosed in Section 3.19 of the
Disclosure Schedule, the Interim Balance Sheet accurately reflects the
inventory, works-in-process and raw materials owned by Rystan as of the date
thereof and Rystan's inventory, works-in-process and raw materials are in all
material respects within specifications and fit for their intended commercial
use and purpose.

         SECTION 3.20. Investment Intent. Except in accordance with applicable
law: (a) GWC is acquiring the Integra Securities for investment for its own
account, not as a



                                 -17-

nominee or agent, and not with a view to the resale or distribution of any part
thereof; (b) GWC has no present intention of selling, granting any participation
in, or otherwise distributing the Integra Securities; and (c) GWC does not have
any contract, undertaking, agreement or arrangement with any person to sell,
transfer or grant participation to such person or to any third person, with
respect to any of the Integra Securities.

         SECTION 3.21. Investment Experience. GWC has such knowledge and
experience in financial and business matters as to be capable of evaluating
the merits and risks of the investment in the Integra Securities. GWC is an
"accredited investor" as such term is defined in Rule 501 of the General Rules
and Regulations under the Securities Act.

         SECTION 3.22.  Restricted Securities; Certain Acknowledgments.

                  (a) GWC understands that: (i) the Integra Securities are not
         registered under the Securities Act of 1933, as amended (the
         "Securities Act") or qualified under any state securities laws; (ii)
         the Integra Securities are being issued to GWC on the ground that the
         issuance of securities hereunder is exempt from registration under
         the Securities Act and from applicable state securities laws; and
         (iii) Integra's reliance on such exemptions is predicated on GWC's
         representations set forth herein. GWC understands that these
         exemptions only exempt the issuance of the Integra Securities to GWC
         and not any sale or other disposition of the Integra Securities or
         any interest therein by GWC. GWC acknowledges that the Integra
         Securities may not be resold or transferred unless the Integra
         Securities are first registered under federal securities laws or
         unless an exemption from such registration is available, and that any
         resale or transfer must comply with applicable state securities laws.

                  (b) GWC acknowledges receipt of such documents, agreements
         and information concerning Integra as GWC has required and confirms
         that: (i) Integra has afforded GWC the opportunity to ask questions
         of and receive answers from Integra's officers concerning GWC's
         investment in the Integra Securities and to obtain such additional
         information as Seller has requested; and (ii) GWC has availed itself
         of such opportunity to the extent it deems necessary and has received
         the information requested.

         SECTION 3.23.  Insurance.

                  (a) The insurance policies disclosed in Section 3.23 of the
         Disclosure Schedule are sufficient for compliance with applicable
         laws, rules and regulations and agreements to which Rystan is a party
         or by which it or its assets are bound, are valid and enforceable and
         will not be affected by, terminate or lapse prior to the Effective
         Time by reason of the transactions contemplated by this Agreement.

                  (b) Rystan has not received: (i) any written notice or, to
         GWC's knowledge, other notice of cancellation of any insurance policy
         disclosed in Section 3.23 of the Disclosure Schedule or refusal of
         coverage thereunder; (ii) any written notice or, to GWC's knowledge,
         other notice that any issuer of such policy has filed




                                 -18-

         for protection under applicable bankruptcy or insolvency laws
         or is otherwise in the process of liquidating or has been
         liquidated; or (iii) any other written indication that any such
         policy may no longer be in full force or effect or that the
         issuer of any such policy may no longer be willing or able to
         perform its obligations thereunder.

                  (c) Schedule 3.23 of the Disclosure Schedule identifies any
         retrospective premium adjustments and outstanding claims or notices
         of claims under the insurance policies disclosed therein.

         SECTION 3.24. Customers and Suppliers; Warranties. Except as
disclosed in Section 3.24 of the Disclosure Schedule: (a) no customer that
accounted for more than 10% of the gross revenues of Rystan during 1996 or
1997 has terminated or materially reduced, or has given written notice that it
intends to terminate or materially reduce, the amount of business done with
Rystan; (b) no supplier or vendor that accounted for more than $20,000 of the
purchases of Rystan during 1996 or 1997 has terminated or materially reduced,
or has given written notice that it intends to terminate or materially reduce,
the amount of business done with Rystan; and (c) Rystan has not expressly
agreed in writing to become responsible for consequential damages or, to GWC's
knowledge, made any express written warranties to third parties with respect
to any products created, manufactured, sold, distributed or licensed, or any
services rendered, by Rystan.

         SECTION 3.25. Certain Disclosure. To GWC's knowledge, there are no
obligations or liabilities of Rystan existing as of the date hereof which are
created by, or identified specifically as being obligations of Rystan in, the
Agreement and Plan Merger dated April 21, 1998 among Elan Corporation, plc,
GWC Merger Co. and GWC which have not been disclosed to Integra in this
Agreement or the Disclosure Schedule.

                                  ARTICLE IV

                   REPRESENTATIONS AND WARRANTIES OF INTEGRA

         Integra represents and warrants to GWC that:

         SECTION 4.01. Organization. Integra is a corporation duly
incorporated, validly existing and in good standing under the laws of the
State of Delaware. Merger Sub is a corporation duly incorporated, validly
existing and in good standing under the laws of the State of New Jersey.

         SECTION 4.02. Capitalization. The authorized capital stock of Integra
consists of 60,000,000 shares of Integra Common Stock and 15,000,000 shares of
Preferred Stock, par value $.01 per share, of which 2,000,000 shares have been
designated as Series A Convertible Preferred Stock ("Series A Preferred
Stock"). As of the date of this Agreement, there are 14,893,654 shares of
Integra Common Stock and 500,000 shares of Series A Preferred Stock
outstanding. Except as disclosed in the SEC Filings or issued in the ordinary
course of business under plans disclosed in the SEC Filings, there are no
existing options, warrants,



                                 -19-

calls, subscriptions, or other similar rights, commitments or agreements
obligating Integra to issue, transfer or sell any shares of capital
stock of Integra or any other securities convertible into or evidencing
the right to subscribe for any shares of capital stock of Integra.
Except as disclosed in the SEC Filings, no person has any registration
rights with respect to any Integra Common Stock or Series A Preferred
Stock. There are no outstanding stock appreciation rights with respect
to Integra Common Stock. Integra directly owns all of the outstanding
shares of capital stock of Merger Sub free and clear of any Liens.

         SECTION 4.03.  Authority; Due Execution.

                  (a) Integra has all necessary corporate power and authority
         to execute and deliver this Agreement, the Registration Rights
         Agreement and the Integra Warrants and to consummate the transactions
         contemplated hereby and thereby. The execution and delivery of this
         Agreement, the Registration Rights Agreement and the Integra Warrants
         by Integra and the consummation by Integra of the transactions
         contemplated hereby and thereby have been duly and validly authorized
         by all necessary corporate action and no other proceedings on the
         part of Integra are necessary to authorize this Agreement or to
         consummate the transactions contemplated hereby. Each of this
         Agreement, the Registration Rights Agreement and the Integra Warrants
         has been duly and validly executed and delivered by Integra and,
         assuming the due authorization, execution and delivery hereof and
         thereof by the other parties thereto, if any, constitutes a valid and
         binding obligation of Integra, enforceable against Integra in
         accordance with its terms, subject to bankruptcy, insolvency,
         fraudulent transfer, reorganization, moratorium and other laws of
         general applicability relating to or affecting creditors' rights and
         to general equity principles.

                  (b) Merger Sub has all necessary corporate and shareholder
         power and authority to execute and deliver this Agreement and to
         consummate the transactions contemplated hereby. The execution and
         delivery of this Agreement by Merger Sub and the consummation by
         Merger Sub of the transactions contemplated hereby have been duly and
         validly authorized by all necessary corporate and shareholder action
         and no other proceedings on the part of Merger Sub or its shareholder
         are necessary to authorize this Agreement or to consummate the
         transactions contemplated hereby. This Agreement has been duly and
         validly executed and delivered by Merger Sub and, assuming the due
         authorization, execution and delivery thereof by the other parties
         hereto, constitutes a valid and binding obligation of Merger Sub,
         enforceable against Merger Sub in accordance with its terms, subject
         to bankruptcy, insolvency, fraudulent transfer, reorganization,
         moratorium and other laws of general applicability relating to or
         affecting creditors' rights and to general equity principles.

                  (c) The Surviving Corporation has all necessary corporate
         power and authority to execute and deliver the Lease and to
         consummate the transactions contemplated thereby. The execution and
         delivery of the Lease by the Surviving Corporation and the
         consummation by the Surviving Corporation of the transactions
         contemplated thereby have been duly and validly authorized by all
         necessary corporate



                                 -20-

         action and no other corporate proceedings on the part of the
         Surviving Corporation are necessary to authorize the Lease or
         to consummate the transactions contemplated thereby. The Lease
         has been duly and validly executed and delivered by the
         Surviving Corporation and, assuming the due authorization,
         execution and delivery thereof by GWC, constitutes a valid and
         binding obligation of the Surviving Corporation, enforceable
         against the Surviving Corporation in accordance with its terms,
         subject to bankruptcy, insolvency, fraudulent transfer,
         reorganization, moratorium and other laws of general
         applicability relating to or affecting creditors' rights and to
         general equity principles.

         SECTION 4.04. Integra Securities. The Integra Securities are duly
authorized and validly issued, fully paid and non-assessable and free and
clear of any Liens. The Integra Securities have not been issued in violation
of or subject to any preemptive rights of any person. When issued and paid for
in accordance with the terms of the Integra Warrants, the shares of Integra
Common Stock issuable upon exercise of the Integra Warrants will be duly
authorized and validly issued, fully paid and non-assessable and free and
clear of any Liens.

         SECTION 4.05. No Violations. Except for the filing of the Certificate
of Merger with the Secretary of State of the State of New Jersey, no filing
with, notification to or permit, authorization, consent or approval of, any
Governmental Authority is necessary on the part of Integra or Merger Sub for
the consummation by Integra or Merger Sub of the transactions contemplated
hereby, except for notices required to be filed with certain state and federal
securities commissions after the Effective Time, which notices will be filed
on a timely basis, and except for filings, notifications, permits,
authorizations, consents or approvals, the failure of which to make, receive
or obtain are not reasonably likely to, individually or in the aggregate,
impair the ability of Integra or Merger Sub to consummate the transactions
contemplated hereby. The execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby do not (i) conflict with
or breach any provision of the Articles of Incorporation or By-laws of Integra
or Merger Sub, (ii) violate any order, writ, injunction, decree, statute, rule
or regulation applicable to Integra or Merger Sub or any of their respective
properties or assets, (iii) result in, require or permit the creation or
imposition of any Lien upon or with respect to the Integra Securities or the
shares of Integra Common Stock issuable upon exercise of the Integra Warrants
or (iv) violate, breach or constitute a default under, any agreement or other
instrument to which Integra or Merger Sub is a party, excluding such
violations, breaches and defaults that, individually or in the aggregate, are
not reasonably likely to impair the ability of Integra or Merger Sub to
consummate the transactions contemplated hereby or that have not had and are
not reasonably likely to have, individually or in the aggregate, an Integra
Material Adverse Effect.

         SECTION 4.06. SEC Filings. Integra has timely filed all reports,
registration statements and other documents required to be filed by it (the
"SEC Filings") under the Securities Act and the Securities Exchange Act of
1934, as amended (the "Exchange Act"). The SEC Filings were prepared in
accordance and complied in all material respects with the



                                 -21-

applicable requirements of the Securities Act or the Exchange Act, as
the case may be. None of such SEC Filings, including, without
limitation, any financial statements, exhibits and schedules included
therein and documents incorporated therein by reference, at the time
filed, declared effective or mailed, as the case may be, contained an
untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were
made, not misleading.

         SECTION 4.07. Litigation. Except as disclosed in the SEC Filings,
there are no claims, actions, proceedings or investigations pending or, to
Integra's knowledge, threatened against Integra or Merger Sub or any asset of
Integra or Merger Sub before any court, arbitrator or Governmental Authority
that, individually or in the aggregate, would impair the ability of Integra or
Merger Sub to consummate the transactions contemplated hereby. As of the date
hereof, neither Integra nor Merger Sub nor any asset of Integra or Merger Sub
is subject to any order, writ, judgment, injunction, decree, determination or
award that would, individually or in the aggregate, impair ability of Integra
or Merger Sub to consummate the transactions contemplated hereby.

         SECTION 4.08. Finders or Brokers. Neither Integra nor any of its
affiliates has employed any investment banker, broker, finder or intermediary
in connection with the transactions contemplated hereby who may reasonably be
expected to be entitled to a fee or any commission, directly or indirectly,
from any such person.

         SECTION 4.09. Certain Acknowledgments. Integra acknowledges receipt
of such documents, agreements and information concerning GWC and Rystan as
Integra has required and confirms that: (i) GWC and Rystan have afforded
Integra the opportunity to ask questions of and receive answers from GWC's and
Rystan's officers concerning Integra's acquisition of Rystan and to obtain
such additional information as Integra has requested; and (ii) Integra has
availed itself of such opportunity to the extent it deems necessary and has
received the information requested.

         SECTION 4.10. Absence of Changes or Events. Except as disclosed in
writing by Integra to GWC, since June 30, 1998, Integra has not taken any
action or suffered any change (other than ongoing operating losses incurred by
Integra) that has had or is reasonably likely to have, individually or in the
aggregate, an Integra Material Adverse Effect.




                                 -22-

                              ARTICLE V

                              COVENANTS

         SECTION 5.01. Further Assurances. Subject to the terms and conditions
herein provided, each of the parties hereto shall use all commercially
reasonable efforts to take, or cause to be taken, all other actions and do, or
cause to be done, all other things necessary, proper or appropriate under
applicable laws and regulations to consummate and make effective the
transactions contemplated by this Agreement, including, without limitation,
obtaining of all necessary consents, approvals or waivers for and lifting any
legal bar to the consummation of the transactions contemplated hereby. Each of
the parties hereto shall perform all of its obligations under this Agreement
and shall not take any action that would cause any other party to fail to
perform its obligations hereunder.

         SECTION 5.02. Public Announcements. Before any party hereto issues
any press release or otherwise makes any public statement with respect to this
Agreement or any of the transactions contemplated hereby, such party will
consult with the other parties hereto as to its form and substance and shall
not issue any such press release or make any such public statement prior to
obtaining the other parties' consent (which consent will not be unreasonably
withheld or delayed), except as may be required by law.

         SECTION 5.03.  Employees and Employee Benefits.

                  (a) Effective as of the Effective Time, all employees of
         Rystan immediately prior to the Effective Time (other than those on
         long-term disability and those that are and have been on leave of
         absence for six months or longer) shall become employees of the
         Surviving Corporation ("Surviving Corporation Employees") and shall
         cease active participation in all Employee Benefit Plans that are not
         maintained by Integra or the Surviving Corporation.

                  (b) Effective as of the Effective Time, Surviving
         Corporation Employees who immediately prior to the Effective Time
         were participants in the Carnrick Employees' Incentive and Savings
         Plan (the "Carnrick 401(k) Plan") shall cease to be eligible for any
         future contributions to the Carnrick 401(k) Plan, shall have a fully
         vested and non-forfeitable interest in their vested and unvested
         account balances in the Carnrick 401(k) Plan, and shall be entitled
         to a distribution of their account balances under the Carnrick 401(k)
         Plan in accordance with and to the extent permitted by Section
         401(k)(10) of the Code and other applicable provisions of the Code.
         Surviving Corporation Employees who receive an eligible rollover
         distribution (within the meaning of Section 402(f)(2) of the Code,
         including a direct rollover distribution with the meaning of Section
         401(a)(31) of the Code) from the Carnrick 401(k) Plan shall, subject
         to the provisions of Section 402 of the Code and upon presentation of
         an IRS favorable determination letter with respect to the Carnrick
         401(k) Plan and an



                                 -23-

         opinion of counsel satisfactory to Integra, be permitted to make a 
         rollover contribution to a defined contribution plan of Integra.

                  (c) Effective as of October 1, 1998, Surviving Corporation
         Employees and their covered dependents shall be eligible to enroll in
         such welfare plans (as defined in Section 3(1) of ERISA) as Integra
         or the Surviving Corporation shall make available to new employees
         hired by the Surviving Corporation after the Effective Time (the
         "Surviving Corporation Welfare Plans") and shall (except for the
         obligation under the next sentence and under paragraph (d) of this
         Section 5.03) be otherwise subject to the terms and conditions of
         such Surviving Corporation Welfare Plans. Effective as of October 1,
         1998, Surviving Corporation Employees shall be eligible to enroll in
         Surviving Corporation Welfare Plans which provide medical benefits
         without (i) any waiting periods, (ii) any evidence of insurability
         and (iii) application of any pre-existing physical or mental
         condition, restrictions, except to the extent that such waiting
         periods, evidence of insurability, or pre-existing mental or physical
         condition restrictions would apply under GWC's welfare plans and be
         permitted by law.

                  (d) The Surviving Corporation shall have responsibility for
         "continuation coverage" obligations with respect to Surviving
         Corporation Employees and "qualified beneficiaries" of such Surviving
         Corporation Employees for whom a "qualifying event" occurs on or
         after October 1, 1998. The phrases "continuation coverage, "qualified
         beneficiaries" and "qualifying event" shall have the meaning ascribed
         to them in Section 4980B of the Code and Section 601-608 of ERISA.

                  (e) The parties hereto expressly acknowledge that the
         Surviving Corporation shall be obligated to pay all liabilities under
         the employee benefit plans that are maintained for Surviving
         Corporation Employees to or in respect of any Surviving Corporation
         Employee terminated for any reason at or after the Effective Time,
         including, without limitation, any liability triggered under any
         employment compensation or government-mandated benefits relating to
         the termination of any Surviving Corporation Employee at or after the
         Effective Time, including, without limitation, under the Workers
         Adjustment and Retraining Notification Act of 1998.

                  (f) The parties hereto expressly acknowledge that Integra
         and the Surviving Corporation shall not be obligated to pay any
         liabilities under the employee benefit plans that were maintained for
         Rystan employees to or in respect of any such employee terminated for
         any reason prior to the Effective Time (but not those on short-term
         disability or leave of absence), including, without limitation, any
         liability triggered under any employment compensation or
         government-mandated benefits relating to the termination of any such
         employee prior to the Effective Time, including, without limitation,
         under the Workers Adjustment and Retraining Notification Act of 1988.
         The parties hereto acknowledge that Rystan employees on short-term
         disability or leave of absence for fewer than six months at the
         Effective



                                 -24-

         Time shall not be deemed to have been terminated prior to the 
         Effective Time for purposes of this Section 5.03(f).

                  (g) Integra shall cause the Surviving Corporation to offer
         compensation and benefits to Surviving Corporation Employees that are
         substantially equivalent when taken as a whole to the compensation
         and benefits that such employees enjoyed before the Effective Time;
         provided that nothing in this Section 5.03(g) shall obligate the
         Surviving Corporation to renew any employment agreement after its
         expiration or termination or preclude the Surviving Corporation from
         terminating Surviving Corporation Employees employed at will after
         October 1, 1998.

         SECTION 5.04.  Certain Restrictive Covenants.

                  (a) From and after the Effective Time, GWC shall not
         disclose, directly or indirectly, to any person other than directors,
         officers, employees or agents of Integra or the Surviving
         Corporation, without the express authorization of Integra, any
         customer lists, pricing strategies, customer and employee files and
         records, any proprietary data or trade secrets of the Surviving
         Corporation, or any financial or other information about the
         Surviving Corporation not in the public domain.

                  (b) For a period of two years from and after the Effective
         Time, GWC shall not solicit the Surviving Corporation's customers,
         suppliers, employees or independent contractors to cease doing
         business, or their association or employment, with the Surviving
         Corporation.

                  (c) GWC expressly acknowledges that damages alone may be an
         inadequate remedy for any breach or violation of any of the
         provisions of this Section 5.04, and that Integra, in addition to all
         other remedies under this Agreement, shall be entitled to seek
         injunctive relief, including specific performance, with respect to
         any such breach or violation, in any court of competent jurisdiction.

                  (d) The invalidity or unenforceability of any provision of
         this Section 5.04 shall not affect the validity or enforceability of
         any other provision of this Section 5.04, which shall remain in full
         force and effect, and in the event that any provision of this Section
         5.04 shall be determined to be invalid or unenforceable for any
         reason, such provision shall be construed by limiting it so as to be
         valid and enforceable to the fullest extent compatible with and
         possible under applicable law.

         SECTION 5.05. Costs and Expenses. GWC shall pay its fees and expenses
and those of its agents and advisors incurred in connection with the
transactions contemplated by this Agreement (including, without limitation,
all legal and accounting fees (collectively, "Transaction Costs")); it being
agreed that the proposed acquisition of Rystan contemplated by this Agreement
is not in the ordinary course of Rystan's business, that Rystan has not
incurred or paid any Rystan Transaction Costs and that none of GWC's
Transaction Costs incurred in connection with the transactions contemplated
hereby have been or shall be borne by Rystan.



                                 -25-

         SECTION 5.06. Consulting Arrangement. At the request of Integra, GWC
shall make Edmond J. Bergeron available to Integra and the Surviving
Corporation for consulting services through June 30, 1999 at a cost of $250
per hour payable to GWC, such consulting services to be provided at such times
as will not unreasonably interfere with Mr. Bergeron's duties as an officer
and director of GWC and, in any event, not to exceed three hours during any
calendar quarter without the mutual consent of GWC and Integra.

         SECTION 5.07. Packaging. GWC agrees to utilize the Surviving
Corporation to package for GWC the products packaged by Rystan immediately
prior to the Effective Time on substantially the same terms and conditions as
in effect immediately prior to the Effective Time, unless and until either
party gives the other party 60 days prior written notice of its intention to
terminate such arrangement.

                              ARTICLE VI

                           INDEMNIFICATION

         SECTION 6.01. Survival. Notwithstanding any otherwise applicable
statute of limitations and despite any investigations made prior to the
Effective Time, the representations and warranties made by GWC and Integra in
this Agreement shall survive the Effective Time until May 1, 1999; except that
the representations and warranties set forth in (a) Section 3.15 shall survive
the Effective Time until the expiration of all applicable statutes of
limitations, (b) Section 3.16(f) shall survive the Effective Time indefinitely
and (c) Sections 3.16(a), (b), (c), (d) and (e) shall survive the Effective
Time until the latter to occur of (i) the third anniversary of the sale or
other disposition by GWC to a non-affiliate, third party of the Property and
(ii) the eighth anniversary of the date of this Agreement.

         SECTION 6.02.  Indemnification by GWC.

                  (a) Subject to the provisions of Sections 6.02(b) and (c),
         GWC shall indemnify and hold harmless Integra, the Surviving
         Corporation and their respective officers, directors, employees and
         agents (each, an "Integra Indemnified Party") from and against any
         and all losses, liabilities and damages, including, without
         limitation, reasonable costs and fees of counsel, resulting from any
         breach of the covenants, representations and warranties made by GWC
         in this Agreement (collectively, "Integra Losses"). The Integra
         Indemnified Parties shall use all commercially reasonable efforts to
         mitigate all Integra Losses.

                  (b) Except as provided in Section 6.02(c), in no event shall
         GWC be liable to any Integra Indemnified Party pursuant to this
         Article VI for Integra Losses (excluding Integra Losses resulting
         from a breach by GWC of Sections 3.15, 3.16, 5.01, 5.02, 5.03, 5.04,
         5.05, 5.07, 7.01, 7.04 and 7.07) unless and until all Integra Losses
         (excluding Integra Losses resulting from a breach by GWC of Sections
         3.15, 3.16, 5.01, 5.02, 5.03, 5.04, 5.05, 5.07, 7.01, 7.04 and 7.07)
         of the Integra Indemnified Parties exceed, in the aggregate, $75,000,
         in which case the Integra Indemnified



                                 -26-

         Parties shall be entitled to recover the portion of such
         aggregate Integra Losses in excess of $75,000 up to an amount
         which does not exceed $1,500,000.

                  (c) Subject to the provisions of Section 6.02(d), GWC shall
         be liable to the Integra Indemnified Parties, without duplication,
         for Integra Losses resulting from a breach by GWC of (i) Sections
         3.15, 3.16(f), 5.01, 5.02, 5.03, 5.04, 5.05, 5.07, 7.01, 7.04 and
         7.07) on a dollar for dollar basis, without limitation, and (ii)
         Sections 3.16(a), (b), (c), (d) and (e), collectively, on the
         following basis: (x) 50% for the first $4,000,000 of such Integra
         Losses ("Layer A"); (y) 100% for the next $6,000,000 of such Integra
         Losses in excess of Layer A ("Layer B"); and (z) 50% for all such
         Integra Losses in excess of Layer B.

                  (d) The parties hereto agree that in the event an Integra
         Loss results from a breach by GWC of Section 3.16(f) and one or more
         of Sections 3.16(a), (b), (c) and (d), such Integra Loss shall be
         deemed to result from a breach by GWC of Section 3.16(f) only and
         Section 6.02(c)(i) shall govern.

         SECTION 6.03.  Indemnification by Integra.

                  (a) Subject to the provisions of Section 6.03(b), Integra
         shall indemnify and hold harmless GWC and its officers, directors,
         employees and agents (each, a "GWC Indemnified Party") from and
         against any and all losses, liabilities and damages, including,
         without limitation, reasonable costs and fees of counsel, resulting
         from any breach of the covenants, representations and warranties made
         by Integra in this Agreement (collectively, "GWC Losses"). The GWC
         Indemnified Parties shall use all commercially reasonable efforts to
         mitigate all GWC Losses.

                  (b) In no event shall Integra be liable to any GWC
         Indemnified Party pursuant to this Article VI for GWC Losses
         (excluding GWC Losses resulting from a breach by Integra of Sections
         5.01, 5.02, 5.03, 5.07, 7.02, 7.04 and 7.07) unless and until all GWC
         Losses (excluding GWC Losses resulting from a breach by Integra of
         Sections 5.01, 5.02, 5.03, 5.07, 7.02, 7.04 and 7.07) of the GWC
         Indemnified Parties exceed, in the aggregate, $75,000, in which case
         the GWC Indemnified Parties shall be entitled to recover the portion
         of such aggregate GWC Losses in excess of $75,000 up to an amount
         which does not exceed $1,500,000; it being understood that,
         notwithstanding the foregoing, Integra shall be liable to GWC on a
         dollar for dollar basis, without limitation, for GWC Losses resulting
         from a breach by Integra of Sections 5.01, 5.02, 5.03, 5.07, 7.02,
         7.04 or 7.07.

         SECTION 6.04 Procedure. Promptly after acquiring knowledge of any
Integra Loss or GWC Loss (each, a "Loss") or any suit, action, proceeding or
claim (each, a "Claim") which may result in a Loss, an Integra Indemnified
Party or GWC Indemnified Party, as the case may be, shall notify GWC or
Integra, as the case may be, of the same in writing specifying in detail the
nature of such Loss or Claim and the facts pertaining thereto. GWC or Integra,
as the case may be, shall be entitled, but not obligated, to assume the
defense of any such Claim by giving written notice to such Integra Indemnified
Party or GWC Indemnified



                                 -27-

Party, as the case may be, within 30 days after having received written
notice therefrom and to have the sole control of the defense and
settlement thereof (but only, with respect to any settlement, if such
settlement involves an unconditional release of such Integra Indemnified
Party or GWC Indemnified Party, as the case may be, in respect of such
claim), including the retention of counsel and the payment of all fees
and expenses.

         SECTION 6.05.  Measurement of Damages.

                  (a) If any event shall occur which would entitle an Integra
         Indemnified Party or GWC Indemnified Party, as the case may be, to
         indemnification under this Article VI, such Integra Indemnified Party
         or GWC Indemnified Party, as the case may be, shall make claims for
         recovery under any applicable insurance policy with respect to such
         Loss, and no Loss shall be deemed to have been sustained to the
         extent of any net proceeds received by such Integra Indemnified Party
         or GWC Indemnified Party, as the case may be, from any such insurance
         policy; provided, however, that such Integra Indemnified Party or GWC
         Indemnified Party, as the case may be, shall not be required to
         threaten or commence suit or take any similar action to compel
         coverage, or receive any proceeds, under any such insurance policy in
         order to be indemnified for a claim under this Article VI.

         SECTION 6.06. Investigations. The indemnification obligations
contained in this Article VI shall remain in full force and effect regardless
of any investigation made or omitted by an Integra Indemnified Party or GWC
Indemnified Party, as the case may be. SECTION 6.07. Sole Remedy. Except as
otherwise provided in this Agreement, the indemnification rights set forth in
this Article VI shall be the sole remedy available to the Integra Indemnified
Parties and GWC Indemnified Parties for all matters covered by this Agreement.

                             ARTICLE VII

                             TAX MATTERS

         SECTION 7.01. Tax Indemnification by GWC. GWC shall indemnify and
hold harmless Integra and the Surviving Corporation, without duplication,
against any and all losses, liabilities and damages, including, without
limitation, reasonable costs and fees of counsel, resulting from, arising out
of, relating to, in the nature of or caused by the liability of the Surviving
Corporation for the Taxes of any affiliate of Athena Neurosciences, Inc. or
GWC (not including Rystan) under Treas. Reg. ss. 1.1502-6 (or any similar
provision of state, local or foreign law) for periods during which Rystan was
a member of the affiliated group of Athena Neurosciences, Inc. or GWC for
United States federal income tax purposes.

         SECTION 7.02. Tax Indemnification by Integra. Integra shall indemnify
and hold harmless GWC from and against (a) any and all Taxes (other than Taxes
referred to in Section 7.01 or attributable to a misrepresentation in Section
3.15) with respect to the Surviving Corporation for any period beginning after
the Closing Date and (b) any and all Taxes



                                 -28-

attributable to the acts or omissions of Integra or any affiliate of
Integra (including the Surviving Corporation) (i) after the Closing Date
or (ii) out of the ordinary course of business after the Closing but on
the Closing Date.

         SECTION 7.03. Allocation of Certain Taxes. Any income Taxes for a
taxable period beginning on or prior to the Closing Date and ending after the
Closing Date with respect to the Surviving Corporation shall be apportioned
between GWC and Integra based on a closing of the books of Rystan at the close
of business on the Closing Date. For purposes of the provisions of Sections
7.01, 7.02, 7.03 and 7.05, each portion of such period shall be deemed to be a
taxable period whether or not it is in fact a taxable period.

         SECTION 7.04. Filing Responsibility. GWC shall prepare and file or
shall cause Rystan to prepare and file the following Tax Returns with respect
to Rystan: (a) all consolidated or combined income Tax Returns for any taxable
period ending on or prior to the Closing Date that include GWC; and (b) all
Tax Returns required to be filed (taking into account extensions) prior to the
Effective Time. Integra and the Surviving Corporation will furnish Tax
information to GWC for inclusion in GWC's federal consolidated income Tax
Returns for the period that includes the Closing Date in accordance with
Rystan's past practice. Integra and the Surviving Corporation shall prepare
and file all other Tax Returns with respect to Rystan and/or the Surviving
Corporation.

         SECTION 7.05.  Refunds and Carrybacks.

                  (a) GWC shall be entitled to any refunds or credits of
         income Taxes of GWC, Rystan or their affiliates for taxable periods
         ending on or prior to the Closing Date except that GWC shall pay to
         the Surviving Corporation 50% of any refunds that are attributable to
         any carryback of Tax items generated by the Surviving Corporation
         after the Effective Time.

                  (b) Integra shall or shall cause the Surviving Corporation
         to forward to GWC or to reimburse GWC for any refunds or credits due
         GWC pursuant to this Section 7.05, together with related interest,
         promptly after receipt thereof.

         SECTION 7.06. Cooperation and Exchange of Information. GWC and
Integra and their respective affiliates shall cooperate in the preparation of
all Tax Returns. Such cooperation shall include, but not be limited to,
furnishing such information within such party's possession reasonably
requested by the party filing such Tax Returns as is relevant to their
preparation.

         SECTION 7.07.  Closing Date Balance Sheet.

                  (a) As soon as practicable following the Closing Date, GWC
         shall prepare and deliver to Integra an unaudited balance sheet of
         Rystan as of the close of business on the Closing Date (the "Closing
         Date Balance Sheet"). The Closing Date Balance Sheet shall be
         prepared in accordance with United States generally accepted
         accounting principles consistently applied (except as may be
         indicated therein). Integra shall have 30 days to review the Closing
         Date Balance Sheet, during which



                                 -29-

         time it shall have reasonable access to all relevant books and
         records, employees and accountants of Rystan to the extent
         necessary to complete its review. Unless Integra shall deliver
         written notice to GWC on or prior to the 30th day following
         receipt of the Closing Date Balance Sheet of its objection to
         the Closing Date Balance Sheet, which notice shall specify in
         detail each disputed item and the basis therefor, Integra shall
         be deemed to have accepted and agreed to the Closing Date
         Balance Sheet. In the event Integra so notifies GWC of its
         objection to the Closing Date Balance Sheet, GWC and Integra
         shall attempt in good faith to resolve their differences, and
         any resolution by them as to any disputed item shall be set
         forth in a memorandum of agreement and shall be final, binding
         and conclusive.

                  (b) Based on the Closing Date Balance Sheet, the Surviving
         Corporation shall pay to GWC an amount equal to Rystan's liability
         for income taxes for all taxable periods ended during the period
         beginning January 1, 1998 and ending the Closing Date (other than
         state taxes payable on a separate company basis).

                                 ARTICLE VIII

                                 MISCELLANEOUS

         SECTION 8.01. Amendment and Modification. Subject to applicable law,
this Agreement may be amended, modified or supplemented only by written
agreement of the parties hereto with respect to any of the terms contained
herein.

         SECTION 8.02. Waiver of Compliance; Consents. Any failure of any
party hereto to comply with any obligation, covenant, agreement or condition
herein may be waived by the other parties hereto only by a written instrument
signed by the parties granting such waiver, but such waiver of or failure to
insist upon strict compliance with such obligation, covenant, agreement or
condition shall not operate as a waiver of, or estoppel with respect to, any
subsequent or other failure, except as otherwise provided in such instrument.
Whenever this Agreement requires or permits consent by or on behalf of any
party hereto, such consent shall be given in writing in a manner consistent
with the requirements for a waiver of compliance as set forth in this Section
8.02.

         SECTION 8.03. Tax Opinion. Prior to the Effective Time, GWC shall
have received an opinion of Cahill Gordon & Reindel, counsel to GWC, dated the
Closing Date, to the effect that the Merger shall qualify as a reorganization
within the meaning of Section 368(a) of the Code.

         SECTION 8.04. Notices. All notices and other communications hereunder
shall be in writing and shall be delivered personally, by next-day courier or
telecopied with written confirmation of receipt, to the parties at the
addresses specified below (or at such other address for a party as shall be
specified by like notice):



                                 -30-

                  if to GWC or Rystan:

                           Elan Corporation, plc
                           Lincoln House
                           Lincoln Place
                           Dublin 2, IRELAND
                           Telecopy:  353-1-662-4960
                           Attention:  General Counsel

                      with a copy to:

                           Cahill Gordon & Reindel
                           80 Pine Street
                           New York, New York  10005
                           Telecopy:  (212) 269-5420
                           Attention:  William M. Hartnett, Esq.

                           and

                           Athena Neurosciences, Inc.
                           800 Gateway Boulevard
                           South San Francisco, California  94080
                           Telecopy:  (650) 875-3620
                           Attention:  General Counsel

                  if to Integra or the Surviving Corporation:

                           Integra LifeSciences Corporation
                           105 Morgan Lane
                           Plainsboro, New Jersey  08536
                           Telecopy:  (609) 799-3297
                           Attention:  President

                      with a copy to:

                           Drinker Biddle & Reath LLP
                           105 College Road East
                           Princeton, New Jersey  08542
                           Telecopy:  (609) 799-7000
                           Attention:  John E. Stoddard III, Esq.

Any such notice shall be effective upon receipt, if personally delivered or
telecopied, or one day after delivery to a courier for next-day delivery;
provided that notices of a change of address shall be effective only upon
receipt thereof.

         SECTION 8.05. Assignment; Third Party Beneficiaries. This Agreement
and all of the provisions hereof shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and permitted
assigns, but neither this Agreement nor any of the



                                 -31-

rights, interests or obligations hereunder shall be assigned by any of
the parties hereto without the prior written consent of other the
parties hereto. This Agreement is not intended to confer any rights or
remedies hereunder upon any other person except the parties hereto and,
with respect to Article VI, the respective officers, directors,
employees and agents of Integra, the Surviving Corporation and GWC.

         SECTION 8.06. Governing Law. This Agreement shall be governed by the
laws of the State of New York (regardless of the laws that might otherwise
govern under applicable New York principles of conflicts of law) as to all
matters, including, but not limited to, matters of validity, construction,
effect, performance and remedies. The parties hereby irrevocably submit to the
jurisdiction of the courts of the United States of America located in the
County of New York in respect of the interpretation and enforcement of the
provisions of this Agreement, and hereby waive, and agree not to assert, as a
defense in any action, suit or proceeding for the interpretation or
enforcement hereof, that it is not subject to such jurisdiction or that such
action, suit or proceeding may not be brought or is not maintainable in said
courts or that the venue thereof may not be appropriate or that this Agreement
may not be enforced in or by such courts.

         SECTION 8.07. Severability. In case any one or more of the provisions
contained in this Agreement should be invalid, illegal or unenforceable in any
respect against a party hereto, the validity, legality and enforceability of
the remaining provisions contained herein shall not in any way be affected or
impaired thereby and such invalidity, illegality or unenforceability shall
only apply as to such party in the specific jurisdiction where such judgment
shall be made.

         SECTION 8.08. Interpretation. The Article and Section headings
contained in this Agreement are solely for the purpose of reference, are not
part of the agreement of the parties and shall not in any way affect the
meaning or interpretation of this Agreement.

         SECTION 8.09. Entire Agreement. This Agreement, including all
Exhibits and the Disclosure Schedule, embodies the entire agreement and
understanding of the parties hereto in respect of the subject matter contained
herein. There are no representations, promises, warranties, covenants, or
undertakings other than those expressly set forth or referred to herein.

         SECTION 8.10. Counterparts. This Agreement may be executed and
delivered (including by telecopier) in one or more counterparts, and by the
different parties hereto in separate counterparts, each of which when executed
and delivered shall be deemed to be an original but all of which taken
together shall constitute one and the same agreement.

                                           [Signature Page Follows]





IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the date first written above by their respective officers
thereunto duly authorized.

                                            INTEGRA LIFESCIENCES CORPORATION

                                            By: /s/ David B. Holtz

                                            RC ACQUISITION CORPORATION

                                            By: /s/ David B. Holtz

                                            GWC HEALTH, INC.

                                            By: /s/ Thomas Lynch

                                            RYSTAN COMPANY, INC.

                                            By: /s/ Thomas Lynch




                                                                   Exhibit 4.1



         THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
         1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW, AND MAY NOT
         BE SOLD OR OTHERWISE TRANSFERRED UNLESS IT IS REGISTERED UNDER SUCH
         ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM
         REGISTRATION IS AVAILABLE THEREUNDER.

                                  ---------

                                                      Date: September 28, 1998


                              WARRANT TO PURCHASE
                       150,000 SHARES OF COMMON STOCK OF
                       INTEGRA LIFESCIENCES CORPORATION


                  Void after 5:00 P.M. (Eastern Time) on the
                      Expiration Date (as defined herein)


         THIS CERTIFIES that GWC Health, Inc., a New Jersey corporation (the
"Warrant Holder"), or registered assigns, is entitled to purchase from INTEGRA
LIFESCIENCES CORPORATION (the "Company"), a Delaware corporation, at any time
after the date hereof and until 5:00 P.M. (Eastern Time) on the Expiration
Date, One Hundred Fifty Thousand (150,000) fully paid and nonassessable shares
of Common Stock of the Company, $.01 par value per share (the "Common Stock"),
at a purchase price of $6.00 per share, in each case subject to adjustment as
provided in Section 6 hereof.

         1. Definitions. For the purpose of this Warrant:

         (a) "Expiration Date" shall mean January 31, 2000, provided that if
the average closing price (last trade) of the Common Stock on the NASDAQ
National Market for the relevant Trading Period (as defined herein) is less
than $8.00 per share (appropriately adjusted for stock splits, reverse stock
splits, reclassifications and the like), then the Expiration Date shall be
extended by one year, but in no event shall the Expiration Date be extended
beyond January 31, 2003.

         (b) "Trading Period" shall mean the thirty (30) trading days ending
on the fifth day immediately preceding the then-current Expiration Date. 





         (c) "Warrant Price" shall mean the price per share at which shares of
Common Stock of the Company are purchasable hereunder, as such price may be
adjusted from time to time hereunder. 

         (d) "Warrant Shares" shall mean the Common Stock purchased upon
exercise of Warrants. 

         (e) "Warrants" shall mean this original Warrant to purchase Common
Stock of the Company and any and all Warrants which are issued in exchange or
substitution for the Warrant pursuant to the terms of that Warrant. 

         2. Method of Exercise of Warrants. This Warrant may be exercised at
any time after the date hereof and prior to 5:00 P.M. (Eastern Time) on the
Expiration Date, in whole or in part (but not as to fractional shares), by the
surrender of the Warrant, manually or by facsimile transmission, with the
Purchase Agreement attached hereto as Exhibit A properly completed and duly
executed, at the principal office of the Company at 105 Morgan Lane,
Plainsboro, New Jersey 08536, facsimile number (609) 799-3297, or such other
location which shall at that time be the principal office of the Company (the
"Principal Office"), and upon payment to it by certified check or bank draft
or wire transfer of immediately available funds to the order of the Company of
the purchase price for the shares to be purchased upon such exercise. The
person entitled to the shares so purchased shall be treated for all purposes
as the holder of such shares as of the close of business on the date of
exercise and certificates for the shares of stock so purchased shall be
delivered to the person so entitled within a reasonable time, not exceeding
thirty (30) days, after such exercise. Unless this Warrant has expired, a new
Warrant of like tenor and for such number of shares as the holder of this
Warrant shall direct, representing in the aggregate the right to purchase a
number of shares with respect to which this Warrant shall not have been
exercised, shall also be issued to the holder of this Warrant within such
time.

         3. Exchange. This Warrant is exchangeable, upon the surrender thereof
by the holder thereof at the Principal Office of the Company, for new Warrants
of like tenor registered in such holder's name and representing in the
aggregate the right to purchase the number of shares purchasable under the
Warrant being exchanged, each of such new Warrants to represent the right to
subscribe for and purchase such number of shares as shall be designated by
said holder at the time of such surrender. 

         4. Transfer. Subject to restrictions on transfer set forth herein,
this Warrant is transferable, in whole or in part, at the Principal Office of
the Company by the holder thereof, in person or by duly authorized attorney,
upon presentation of this Warrant, properly endorsed, for transfer. Each
holder of this Warrant, by holding it, agrees that the Warrant, when endorsed
in blank, may be deemed negotiable, and that the holder thereof, when the
Warrant shall have been so endorsed, may be treated by the Company and all
other persons dealing with the Warrant as the absolute owner thereof for any
purpose and as the person entitled to exercise the rights represented by the
Warrant, or to the transfer thereof on the books of the Company, any notice to
the contrary notwithstanding. 

         5. Certain Covenants of the Company. The Company covenants and agrees
that all shares which may be issued upon the exercise of this Warrant, will,
upon issuance, be duly authorized and validly issued, fully paid and
nonassessable and free and clear of any liens or 



                                     -2-



encumbrances whatsoever. The Company covenants and agrees that none of the
shares which may be issued upon the exercise of this Warrant will, upon
issuance, be in violation of or subject to any preemptive rights of any
person. The Company further covenants and agrees that during the period within
which the rights represented by this Warrant may be exercised, the Company
will at all times have authorized, and reserved for the purpose of issue upon
exercise of the purchase rights evidenced by this Warrant, a sufficient number
of shares of its Common Stock to provide for the exercise of the rights
represented by this Warrant. 

         6. Adjustment of Purchase Price and Number of Shares. The number and
kind of securities purchasable upon the exercise of the Warrants and the
Warrant Price shall be subject to adjustment from time to time upon the
happening of certain events as follows: 

         (a) Reclassification, Consolidation or Merger. At any time while the
Warrants remain outstanding and unexpired, in case of any reclassification or
change of outstanding securities issuable upon exercise of the Warrants (other
than a change in par value, or from par value to no par value, or from no par
value to par value or as a result of a subdivision or combination of
outstanding securities issuable upon the exercise of the Warrants) or in case
of any consolidation or merger of the Company with or into another corporation
(other than a merger with another corporation in which the Company is a
continuing corporation and which does not result in any reclassification or
change of rights of outstanding securities issuable upon exercise of the
Warrants, other than a change in par value, or from par value to no par value,
or from no par value to par value, or as a result of a subdivision or
combination of outstanding securities issuable upon exercise of the Warrants),
the Company, or such successor corporation, as the case may be, shall, without
payment of any additional consideration therefor, execute new Warrants
providing that the holders of the Warrants shall have the right to exercise
such new Warrants (upon terms not less favorable to the holders than those
then applicable to the Warrants) and to receive upon such exercise, in lieu of
each share of Common Stock or other security theretofore issuable upon
exercise of the Warrants, the kind and amount of shares of stock, other
securities, money or property receivable upon such reclassification, change,
consolidation or merger by the holder of one share of Common Stock or other
security issuable upon exercise of the Warrants had the Warrants been
exercised immediately prior to such reclassification, change, consolidation or
merger. Such new Warrants shall provide for adjustments which shall be as
nearly equivalent as may be practicable to the adjustments provided for in
this Section 6. The provisions of this subsection 6(a) shall similarly apply
to successive reclassifications, changes, consolidations and mergers.

         (b) Subdivision or Combination of Shares. If the Company at any time
while the Warrants remain outstanding and unexpired shall subdivide or combine
its Common Stock, (i) the Warrant Price shall be proportionately reduced, and
the number of shares of Common Stock for which this Warrant may be exercised
shall be proportionately increased, in case of subdivision of such shares, as
of the effective date of such subdivision, or, if the Company shall take a
record of holders of its Common Stock for the purpose of so subdividing, as of
such record date, whichever is earlier, or (ii) the Warrant Price shall be
proportionately increased, and the number of shares of Common Stock for which
this Warrant may be exercised shall be proportionately reduced, in the case of
combination of such shares, as of the effective date of such combination, or,
if the Company shall take a record of holders of its Common Stock for the
purpose of so combining, as of such record date, whichever is earlier. 



                                     -3-



         (c) Stock Dividends. If the Company at any time while the Warrants
are outstanding and unexpired shall pay a dividend in shares of, or make other
distribution of shares of, its Common Stock, then the Warrant Price shall be
adjusted, as of the date the Company shall take a record of the holders of its
Common Stock for the purpose of receiving such dividend or other distribution
(or if no such record is taken, as at the date of such payment or other
distribution), to that price determined by multiplying the Warrant Price in
effect immediately prior to such payment or other distribution by a fraction
(i) the numerator of which shall be the total number of shares of Common Stock
outstanding immediately prior to such dividend or distribution, and (ii) the
denominator of which shall be the total number of shares of Common Stock
outstanding immediately after such dividend or distribution (the "Fraction"),
and the number of shares of Common Stock issuable upon exercise of this
Warrant shall be adjusted by multiplying such number by the reciprocal of the
Fraction. The number of shares of Common Stock at any time outstanding shall
not include any shares thereof then directly or indirectly owned or held by or
for the account of the Company or any wholly-owned subsidiary. The provisions
of this subsection 6(c) shall not apply under any of the circumstances for
which an adjustment is provided in subsections 6(a) or 6(b). 

         (d) Liquidating Dividends, Etc. If the Company at any time while the
Warrants are outstanding and unexpired makes a distribution of its assets to
the holders of its Common Stock as a dividend in liquidation or by way of
return of capital or other than as a dividend payable out of earnings or
surplus legally available for dividends under applicable law or any
distribution to such holders made in respect of the sale of all or
substantially all of the Company's assets (other than under the circumstances
provided for in the foregoing subsections 6(a) through 6(c)), the Warrant
Holder shall be entitled to receive upon the exercise hereof, in addition to
the shares of Common Stock receivable upon such exercise, and without payment
of any consideration other than the Warrant Price, an amount of such assets so
distributed equal to the value of such distribution per share of Common Stock
multiplied by the number of shares of Common Stock which, on the record date
for such distribution, are issuable upon exercise of this Warrant (with no
further adjustment being made following any event which causes a subsequent
adjustment in the number of shares of Common Stock issuable upon the exercise
hereof), and an appropriate provision therefor shall be made a part of any
such distribution. The value of a distribution which is paid in other than
cash shall be determined by an independent appraiser designated by the Board
of Directors of the Company. 

         (e) Notice of Adjustments. Whenever the Warrant Price or the number
of shares of Common Stock purchasable under the terms of this Warrant at the
Warrant Price shall be adjusted pursuant to this Section 6, the Company shall
promptly prepare a certificate signed by its President or a Vice President and
by its Treasurer or Assistant Treasurer or its Secretary or Assistant
Secretary, setting forth in reasonable detail the event requiring the
adjustment, the amount of the adjustment, the method by which such adjustment
was calculated (including a description of the basis on which the Company's
Board of Directors made any determination hereunder), and the Warrant Price
and number of shares of Common Stock purchasable at that Warrant Price after
giving effect to such adjustment, and shall promptly cause copies of such
certificate to be mailed (by first class and postage prepaid) to the
registered holder of this Warrant. 

         7. Fractional Shares. No fractional shares of the Company's Common
Stock will be issued in connection with any purchase hereunder but in lieu of
such fractional shares, the 



                                     -4-



Company shall make a cash refund therefor equal in amount to the product of
the applicable fraction multiplied by the Warrant Price paid by the holder for
its Warrant Shares upon such exercise.

         8. Loss, Theft, Destruction or Mutilation. Upon receipt by the
Company of evidence reasonably satisfactory to it that any Warrant has been
mutilated, destroyed, lost or stolen, and in the case of any destroyed, lost
or stolen Warrant, a bond of indemnity reasonably satisfactory to the Company,
or in the case of a mutilated Warrant, upon surrender and cancellation
thereof, the Company will execute and deliver in the Warrant Holder's name, in
exchange and substitution for the Warrant so mutilated, destroyed, lost or
stolen, a new Warrant of like tenor substantially in the form thereof with
appropriate insertions and variations. 

         9. Headings. The descriptive headings of the several sections of this
Warrant are inserted for convenience only and do not constitute a part of this
Warrant.

         IN WITNESS WHEREOF, the Company has caused this Warrant to be signed
by its duly authorized officer on the date of this Warrant.

                                              INTEGRA LIFESCIENCES CORPORATION

                                              By: /s/ Stuart M. Essig
                                                  -------------------



                                     -5-



                                                                     Exhibit A

                              PURCHASE AGREEMENT

                                               Date:                      

TO:

         The undersigned, pursuant to the provisions set forth in the attached
Warrant, hereby agrees to purchase ______ shares of Common Stock covered by such
Warrant, and makes payment herewith in full therefor at the price per share
provided by this Warrant.

                                       Signature: 
                                                 ------------------------------


                                       Address: 
                                                 ------------------------------

                                                 ------------------------------

                                                 ------------------------------

                                *      *      *

                                  ASSIGNMENT

                  For Value Received, ________________________________________
hereby sells, assigns and transfers all of the rights of the undersigned under
the within Warrant, with respect to the number of shares of Common Stock
covered by such Warrant, to:

NAME OF ASSIGNEE               ADDRESS                          NO. OF SHARES

Dated:                             Signature:
      ------------------------                ------------------------------


                                   Witness:
                                              ------------------------------




                                                                   Exhibit 4.2



THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW, AND MAY NOT BE SOLD OR
OTHERWISE TRANSFERRED UNLESS IT IS REGISTERED UNDER SUCH ACT AND APPLICABLE
STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE
THEREUNDER.

                                  ---------

                                                      Date: September 28, 1998

                              WARRANT TO PURCHASE
                       150,000 SHARES OF COMMON STOCK OF
                       INTEGRA LIFESCIENCES CORPORATION

                  Void after 5:00 P.M. (Eastern Time) on the
                      Expiration Date (as defined herein)

         THIS CERTIFIES that GWC Health, Inc., a New Jersey corporation (the
"Warrant Holder"), or registered assigns, is entitled to purchase from INTEGRA
LIFESCIENCES CORPORATION (the "Company"), a Delaware corporation, at any time
after the date hereof and until 5:00 P.M. (Eastern Time) on the Expiration
Date, One Hundred Fifty Thousand (150,000) fully paid and nonassessable shares
of Common Stock of the Company, $.01 par value per share (the "Common Stock"),
at a purchase price of $7.00 per share, in each case subject to adjustment as
provided in Section 6 hereof.

         1. Definitions. For the purpose of this Warrant:

         (a) "Expiration Date" shall mean December 31, 2002.

         (b) "Warrant Price" shall mean the price per share at which shares of
Common Stock of the Company are purchasable hereunder, as such price may be
adjusted from time to time hereunder. 

         (c) "Warrant Shares" shall mean the Common Stock purchased upon
exercise of Warrants. 

         (d) "Warrants" shall mean this original Warrant to purchase Common
Stock of the Company and any and all Warrants which are issued in exchange or
substitution for the Warrant pursuant to the terms of that Warrant.



         2. Method of Exercise of Warrants. This Warrant may be exercised at
any time after the date hereof and prior to 5:00 P.M. (Eastern Time) on the
Expiration Date, in whole or in part (but not as to fractional shares), by the
surrender of the Warrant, manually or by facsimile transmission, with the
Purchase Agreement attached hereto as Exhibit A properly completed and duly
executed, at the principal office of the Company at 105 Morgan Lane,
Plainsboro, New Jersey 08536, facsimile number (609) 799-3297, or such other
location which shall at that time be the principal office of the Company (the
"Principal Office"), and upon payment to it by certified check or bank draft
or wire transfer of immediately available funds to the order of the Company of
the purchase price for the shares to be purchased upon such exercise. The
person entitled to the shares so purchased shall be treated for all purposes
as the holder of such shares as of the close of business on the date of
exercise and certificates for the shares of stock so purchased shall be
delivered to the person so entitled within a reasonable time, not exceeding
thirty (30) days, after such exercise. Unless this Warrant has expired, a new
Warrant of like tenor and for such number of shares as the holder of this
Warrant shall direct, representing in the aggregate the right to purchase a
number of shares with respect to which this Warrant shall not have been
exercised, shall also be issued to the holder of this Warrant within such
time.

         3. Exchange. This Warrant is exchangeable, upon the surrender thereof
by the holder thereof at the Principal Office of the Company, for new Warrants
of like tenor registered in such holder's name and representing in the
aggregate the right to purchase the number of shares purchasable under the
Warrant being exchanged, each of such new Warrants to represent the right to
subscribe for and purchase such number of shares as shall be designated by
said holder at the time of such surrender. 

         4. Transfer. Subject to restrictions on transfer set forth herein,
this Warrant is transferable, in whole or in part, at the Principal Office of
the Company by the holder thereof, in person or by duly authorized attorney,
upon presentation of this Warrant, properly endorsed, for transfer. Each
holder of this Warrant, by holding it, agrees that the Warrant, when endorsed
in blank, may be deemed negotiable, and that the holder thereof, when the
Warrant shall have been so endorsed, may be treated by the Company and all
other persons dealing with the Warrant as the absolute owner thereof for any
purpose and as the person entitled to exercise the rights represented by the
Warrant, or to the transfer thereof on the books of the Company, any notice to
the contrary notwithstanding. 

         5. Certain Covenants of the Company. The Company covenants and agrees
that all shares which may be issued upon the exercise of this Warrant, will,
upon issuance, be duly authorized and validly issued, fully paid and
nonassessable and free and clear of any liens or encumbrances whatsoever. The
Company covenants and agrees that none of the shares which may be issued upon
the exercise of this Warrant will, upon issuance, be in violation of or
subject to any preemptive rights of any person. The Company further covenants
and agrees that during the period within which the rights represented by this
Warrant may be exercised, the Company will at all times have authorized, and
reserved for the purpose of issue upon exercise of the purchase rights
evidenced by this Warrant, a sufficient number of shares of its Common Stock
to provide for the exercise of the rights represented by this Warrant. 



                                     -2-



         6. Adjustment of Purchase Price and Number of Shares. The number and
kind of securities purchasable upon the exercise of the Warrants and the
Warrant Price shall be subject to adjustment from time to time upon the
happening of certain events as follows: 

         (a) Reclassification, Consolidation or Merger. At any time while the
Warrants remain outstanding and unexpired, in case of any reclassification or
change of outstanding securities issuable upon exercise of the Warrants (other
than a change in par value, or from par value to no par value, or from no par
value to par value or as a result of a subdivision or combination of
outstanding securities issuable upon the exercise of the Warrants) or in case
of any consolidation or merger of the Company with or into another corporation
(other than a merger with another corporation in which the Company is a
continuing corporation and which does not result in any reclassification or
change of rights of outstanding securities issuable upon exercise of the
Warrants, other than a change in par value, or from par value to no par value,
or from no par value to par value, or as a result of a subdivision or
combination of outstanding securities issuable upon exercise of the Warrants),
the Company, or such successor corporation, as the case may be, shall, without
payment of any additional consideration therefor, execute new Warrants
providing that the holders of the Warrants shall have the right to exercise
such new Warrants (upon terms not less favorable to the holders than those
then applicable to the Warrants) and to receive upon such exercise, in lieu of
each share of Common Stock or other security theretofore issuable upon
exercise of the Warrants, the kind and amount of shares of stock, other
securities, money or property receivable upon such reclassification, change,
consolidation or merger by the holder of one share of Common Stock or other
security issuable upon exercise of the Warrants had the Warrants been
exercised immediately prior to such reclassification, change, consolidation or
merger. Such new Warrants shall provide for adjustments which shall be as
nearly equivalent as may be practicable to the adjustments provided for in
this Section 6. The provisions of this subsection 6(a) shall similarly apply
to successive reclassifications, changes, consolidations and mergers.

         (b) Subdivision or Combination of Shares. If the Company at any time
while the Warrants remain outstanding and unexpired shall subdivide or combine
its Common Stock, (i) the Warrant Price shall be proportionately reduced, and
the number of shares of Common Stock for which this Warrant may be exercised
shall be proportionately increased, in case of subdivision of such shares, as
of the effective date of such subdivision, or, if the Company shall take a
record of holders of its Common Stock for the purpose of so subdividing, as of
such record date, whichever is earlier, or (ii) the Warrant Price shall be
proportionately increased, and the number of shares of Common Stock for which
this Warrant may be exercised shall be proportionately reduced, in the case of
combination of such shares, as of the effective date of such combination, or,
if the Company shall take a record of holders of its Common Stock for the
purpose of so combining, as of such record date, whichever is earlier. 

         (c) Stock Dividends. If the Company at any time while the Warrants
are outstanding and unexpired shall pay a dividend in shares of, or make other
distribution of shares of, its Common Stock, then the Warrant Price shall be
adjusted, as of the date the Company shall take a record of the holders of its
Common Stock for the purpose of receiving such dividend or other distribution
(or if no such record is taken, as at the date of such payment or other
distribution), to that price determined by multiplying the Warrant Price in
effect immediately prior to such payment or other distribution by a fraction
(i) the numerator of which shall be the 



                                     -3-



total number of shares of Common Stock outstanding immediately prior to such
dividend or distribution, and (ii) the denominator of which shall be the total
number of shares of Common Stock outstanding immediately after such dividend
or distribution (the "Fraction"), and the number of shares of Common Stock
issuable upon exercise of this Warrant shall be adjusted by multiplying such
number by the reciprocal of the Fraction. The number of shares of Common Stock
at any time outstanding shall not include any shares thereof then directly or
indirectly owned or held by or for the account of the Company or any
wholly-owned subsidiary. The provisions of this subsection 6(c) shall not
apply under any of the circumstances for which an adjustment is provided in
subsections 6(a) or 6(b). 

         (d) Liquidating Dividends, Etc. If the Company at any time while the
Warrants are outstanding and unexpired makes a distribution of its assets to
the holders of its Common Stock as a dividend in liquidation or by way of
return of capital or other than as a dividend payable out of earnings or
surplus legally available for dividends under applicable law or any
distribution to such holders made in respect of the sale of all or
substantially all of the Company's assets (other than under the circumstances
provided for in the foregoing subsections 6(a) through 6(c)), the Warrant
Holder shall be entitled to receive upon the exercise hereof, in addition to
the shares of Common Stock receivable upon such exercise, and without payment
of any consideration other than the Warrant Price, an amount of such assets so
distributed equal to the value of such distribution per share of Common Stock
multiplied by the number of shares of Common Stock which, on the record date
for such distribution, are issuable upon exercise of this Warrant (with no
further adjustment being made following any event which causes a subsequent
adjustment in the number of shares of Common Stock issuable upon the exercise
hereof), and an appropriate provision therefor shall be made a part of any
such distribution. The value of a distribution which is paid in other than
cash shall be determined by an independent appraiser designated by the Board
of Directors of the Company. 

         (e) Notice of Adjustments. Whenever the Warrant Price or the number
of shares of Common Stock purchasable under the terms of this Warrant at the
Warrant Price shall be adjusted pursuant to this Section 6, the Company shall
promptly prepare a certificate signed by its President or a Vice President and
by its Treasurer or Assistant Treasurer or its Secretary or Assistant
Secretary, setting forth in reasonable detail the event requiring the
adjustment, the amount of the adjustment, the method by which such adjustment
was calculated (including a description of the basis on which the Company's
Board of Directors made any determination hereunder), and the Warrant Price
and number of shares of Common Stock purchasable at that Warrant Price after
giving effect to such adjustment, and shall promptly cause copies of such
certificate to be mailed (by first class and postage prepaid) to the
registered holder of this Warrant. 

         7. Fractional Shares. No fractional shares of the Company's Common
Stock will be issued in connection with any purchase hereunder but in lieu of
such fractional shares, the Company shall make a cash refund therefor equal in
amount to the product of the applicable fraction multiplied by the Warrant
Price paid by the holder for its Warrant Shares upon such exercise.

         8. Loss, Theft, Destruction or Mutilation. Upon receipt by the
Company of evidence reasonably satisfactory to it that any Warrant has been
mutilated, destroyed, lost or stolen, and in the case of any destroyed, lost
or stolen Warrant, a bond of indemnity reasonably 



                                     -4-



satisfactory to the Company, or in the case of a mutilated Warrant, upon
surrender and cancellation thereof, the Company will execute and deliver in
the Warrant Holder's name, in exchange and substitution for the Warrant so
mutilated, destroyed, lost or stolen, a new Warrant of like tenor
substantially in the form thereof with appropriate insertions and variations.

         9. Headings. The descriptive headings of the several sections of this
Warrant are inserted for convenience only and do not constitute a part of this
Warrant.

         IN WITNESS WHEREOF, the Company has caused this Warrant to be signed
by its duly authorized officer on the date of this Warrant.

                                              INTEGRA LIFESCIENCES CORPORATION

                                              By: /s/ Stuart M. Essig
                                                  -------------------



                                     -5-



                                                                     Exhibit A

                              PURCHASE AGREEMENT

                                                Date: 

TO:

         The undersigned, pursuant to the provisions set forth in the attached
Warrant, hereby agrees to purchase ______ shares of Common Stock covered by such
Warrant, and makes payment herewith in full therefor at the price per share
provided by this Warrant.

                                        Signature: 
                                                   ----------------------------

                                        Address:   
                                                   ----------------------------

                                                   ----------------------------

                                                   ----------------------------



                                *      *      *

                                  ASSIGNMENT

                  For Value Received, ________________________________________
hereby sells, assigns and transfers all of the rights of the undersigned under
the within Warrant, with respect to the number of shares of Common Stock
covered by such Warrant, to:

NAME OF ASSIGNEE           ADDRESS                            NO. OF SHARES

Dated:                             Signature:
       --------------------------            -------------------------------
                                   Witness:
                                             -------------------------------



                                                                  Exhibit 10.1



                         REGISTRATION RIGHTS AGREEMENT

         THIS REGISTRATION RIGHTS AGREEMENT, dated as of September 28, 1998
(this "Agreement"), is by and between Integra LifeSciences Corporation, a
Delaware corporation (the "Company"), and GWC Health, Inc., a New Jersey
corporation ("Holder").

                                  BACKGROUND

         The parties hereto are parties to an Agreement and Plan of Merger,
dated as of the date hereof (the "Merger Agreement"), pursuant to which the
Company has agreed to issue to Holder 800,000 shares (the "Shares") of the
Company's common stock, par value $.01 per share (the "Common Stock"), and two
warrants, each to purchase 150,000 shares of Common Stock (the "Warrants"). In
order to induce Holder to enter into the Merger Agreement, the Company has
agreed to provide certain registration rights with respect to the Shares and
the shares of Common Stock issued upon exercise of the Warrants (the "Warrant
Shares" and, together with the Shares, the "Eligible Securities") on the terms
and conditions set forth in this Agreement.

         NOW THEREFORE, in consideration of the premises and the mutual
covenants and agreements contained herein, and intending to be legally bound
hereby, the parties hereto agree as follows:

         1. ACKNOWLEDGEMENTS OF HOLDER

         1.1 Holder acknowledges and understands that, except as set forth in
Sections 2 and 3 hereof, the Company has no obligation or intention to (i)
register the sale of the Warrants or any Eligible Securities under the
Securities Act of 1933, as amended (the "Securities Act," and all regulations
promulgated thereunder are herein collectively referred to as the "Act"), or
applicable state securities or blue sky laws (collectively, "State Securities
Laws"), or (ii) otherwise comply with any requirements necessary for transfer
or assignment of the Warrants or any Eligible Securities to be exempt from
such registration. The Act and State Securities Laws are hereinafter sometimes
collectively referred to as the "Securities Laws."

         1.2 The Eligible Securities and the Warrants are subject to
limitations on transferability under the Securities Laws. 

         1.3 Except as set forth in Sections 2 and 3 hereof, no transfer
(other than to an affiliate of Holder) of the Warrants or any Eligible
Securities shall be effected unless a written opinion of legal counsel that is
acceptable to counsel for the Company shall be delivered to the Company to the
effect that a contemplated transfer may be effected without registration under
the Securities Laws.



         2. DEMAND REGISTRATION

         2.1 Following the exercise in full of either or both of the Warrants,
Holder may make a written request for registration under the Act of all or
part of the Warrant Shares (a "Demand Registration"), which request shall
state the intended method of disposition thereof, and the Company will use
commercially reasonable efforts to cause the Warrant Shares as to which
registration shall have been so requested to be covered by a registration
statement. Holder shall be entitled to request two Demand Registrations. Each
Demand Registration shall be on Form S-3 if such Form is then available for
use by the Company. The Company may exclude the Warrant Shares from
registration pursuant to this Section 2 if the Holder fails to provide
information reasonably requested by the Company with respect to the intended
method of distribution of the Warrant Shares to the public.

         2.2 If the Demand Registration is in the form of an underwritten
offering, the Company shall select the investment banker or investment bankers
and manager or managers that will administer the offering, which investment
bankers or managers shall be reasonably acceptable to Holder. If any of the
Warrant Shares to be registered pursuant to a registration statement filed
pursuant to this Section 2 are to be sold in a firm commitment underwritten
offering, and if the managing underwriter or underwriters advise the Company
in writing that in its or their opinion the aggregate amount of securities
proposed to be sold in such firm commitment underwritten offering by (i) the
Company for its own account, (ii) Holder and (iii) the stockholders of the
Company with respect to securities of the Company other than the Warrant
Shares, would adversely affect the success of such offering, there shall be
included in such firm commitment underwritten offering only the amount of such
securities which in the opinion of such underwriters can be sold in the
proposed underwritten offering, and the amount of such securities shall be
allocated first, to Holder based on the number of Warrant Shares it desires to
sell in the underwritten offering; second, to the Company; and thereafter pro
rata among all selling stockholders, if any (which may include Holder with
respect to the Shares), based on the number of shares (including any of the
Shares) otherwise proposed to be included therein by such selling
stockholders.

         2.3 The Company shall use commercially reasonable efforts to cause
such registration statement to remain effective until the earlier to occur of
(i) 90 days after the effective date of the registration statement or (ii)
until all the Warrant Shares registered for sale are sold pursuant to the
registration statement.

         2.4 The Company's obligations under this Section 2 shall terminate
when Holder may sell or otherwise transfer all Warrant Shares without
registration under the Act by virtue of Rule 144(k) under the Act (or any
similar provision in force).



                                     -2-



         3. PIGGYBACK REGISTRATION

         3.1 If the Company at any time proposes to register any of its Common
Stock under the Act for sale to the public for cash (except with respect to
registration statements on Forms S-8, S-4 or other forms not available for
registering the Eligible Securities for sale to the public), each such time it
will give written notice to Holder of its intention so to do, unless (i) no
stockholders of the Company propose to register or sell their securities in
connection with such offering and (ii) the proceeds to the Company from such
offering (after deduction of underwriting discounts and commissions) are
reasonably expected to be less than $10,000,000. Upon the written request of
Holder, given within 20 days after receipt of any such notice, to register any
of its Eligible Securities (which request shall state the intended method of
disposition thereof), the Company will use commercially reasonable efforts to
cause the Eligible Securities as to which registration shall have been so
requested to be included in the Common Stock to be covered by the registration
statement proposed to be filed by the Company. The Company may exclude the
Eligible Securities of Holder from registration pursuant to this Section 3 if
Holder fails to provide information reasonably requested by the Company with
respect to the intended method of distribution of the Eligible Securities to
the public.

         3.2 (a) If any of the Eligible Securities to be registered pursuant
to a registration statement filed pursuant to this Section 3 are to be sold in
a firm commitment underwritten offering in which the Company proposes to sell
securities for its own account, and if the managing underwriter or
underwriters advise the Company in writing that in its or their opinion the
aggregate amount of securities proposed to be sold in such firm commitment
underwritten offering by (i) the Company for its own account, (ii) Holder and
(iii) the stockholders of the Company with respect to securities of the
Company other than the Eligible Securities, would adversely affect the success
of the Company's sale of its securities in such offering, there shall be
included in such firm commitment underwritten offering only the amount of such
securities which in the opinion of such underwriters can be sold in the
proposed underwritten offering, and the amount of such securities shall be
allocated first, to the Company based on the number of shares it desires to
sell in the underwritten offering for its own account; and thereafter pro rata
among Holder and all other selling stockholders, if any, based on the number
of shares otherwise proposed to be included therein by Holder and such other
selling stockholders.

         (b) If any of the Eligible Securities to be registered pursuant to a
registration statement filed pursuant to this Section 3 are to be sold in a
firm commitment underwritten offering in which the Company does not propose to
sell securities for its own account but in which one or more past, present or
future directors, officers or employees of the Company, their immediate family
members or trusts established for the benefit of any of the foregoing
("Insiders") propose to sell securities, and if the managing underwriter or
underwriters advise the Insiders in writing that in its or their opinion the
aggregate amount of securities proposed to be sold in such firm commitment
underwritten offering by (i) the Insiders, (ii) Holder and (iii) the
stockholders of the Company with respect to securities of the Company other
than the Eligible Securities (the "Other Stockholders"), would adversely
affect the success of such offering, there shall be included in such firm
commitment underwritten offering only the 



                                     -3-



amount of securities which in the opinion of such underwriters can be sold in
the proposed underwritten offering, and the amount of such securities shall be
allocated on a pro rata basis among all selling stockholders (including the
Insiders and Holder), based on the number of shares otherwise proposed to be
included therein by the Insiders, Holder and the Other Stockholders.

         3.3 The Company shall use commercially reasonable efforts to cause
such registration statement to remain effective until the earlier to occur of
(i) 90 days after the effective date of the registration statement or (ii)
until all Eligible Securities registered for sale are sold pursuant to the
registration statement.

         3.4 The Company's obligations under this Section 3 shall terminate
when Holder may sell or otherwise transfer all Eligible Securities without
registration under the Act by virtue of Rule 144(k) under the Act (or any
similar provision in force).

         3.5 Notwithstanding the foregoing provisions in this Section 3, the
Company may delay the effectiveness or withdraw, prior to effectiveness, any
registration statement referred to in this Section 3 without thereby incurring
any liability to Holder. Upon receipt of any notice from the Company of a
delay or withdrawal of a registration statement pursuant to this Section 3,
the Holder shall forthwith discontinue disposition of Eligible Securities
covered by such registration statement.

         4. HOLDBACK AGREEMENTS

         4.1 Except to the extent of any Eligible Securities included in a
registration statement under Sections 2 or 3 hereof, Holder agrees not to
effect any public sale or distribution of securities of the same class as
those being registered or a similar security of the Company, or any securities
convertible into or exchangeable or exercisable for such securities, including
a sale pursuant to Rule 144 under the Act, during the 14 days prior to, and
during the 90-day period beginning on, the effective date of any registration
statement filed by the Company under the Act registering its securities for
sale to the public. If requested by the Company's managing underwriter, Holder
will execute and deliver a lock-up agreement in customary form reasonably
acceptable to such underwriter, Holder and the Company.



                                     -4-



         5. REGISTRATION PROCEDURES

         5.1 If and whenever the Company is required by the provisions of this
Agreement to effect or cause the registration of any Eligible Securities under
the Act pursuant to Sections 2 or 3 hereof, the Company will use commercially
reasonable efforts to effect the registration and the sale of such Eligible
Securities in accordance with the intended method of disposition thereof as
promptly as reasonably practicable, and in connection with any such request,
the Company shall:

         (a) furnish to Holder, and if requested, to Holder's investment
adviser, prior to filing a registration statement, copies of such registration
statement as proposed to be filed, and thereafter such number of copies of
such registration statement, each amendment and supplement thereto (in each
case including all exhibits thereto), the prospectus included in such
registration statement (including each preliminary prospectus) and such other
documents Holder may reasonably request in order to facilitate the disposition
of such Eligible Securities owned by Holder, which are included in such
registration statement;

         (b) use commercially reasonable efforts to register or qualify (or
obtain an exemption from such registration or qualification) such Eligible
Securities under the state securities or blue sky laws of such jurisdictions
as Holder reasonably requests or, in the event of a firm commitment
underwritten offering, such number of jurisdictions as the managing
underwriter or underwriters shall reasonably request, and do any and all other
acts and things which may be reasonably necessary or advisable to enable
Holder to consummate the disposition in such jurisdictions of the Eligible
Securities; provided that the Company will not be required to (i) qualify
generally to do business in any jurisdiction where it would not otherwise be
required to qualify but for this Section 5.1(b), (ii) subject itself to
taxation in any such jurisdiction, or (iii) consent to general service of
process in any such jurisdiction;

         (c) use commercially reasonable efforts to cause the Eligible
Securities covered by such registration statement to be registered with or
approved by such other governmental agencies or authorities as may be
necessary by virtue of the business and operations of the Company to enable
Holder to consummate the disposition of such Eligible Securities;

         (d) notify Holder, at any time when a prospectus relating thereto is
required to be delivered under the Act, of the happening of any event as a
result of which the prospectus included in such registration statement
contains an untrue statement of a material fact or omits to state any material
fact required to be stated therein or necessary to make the statements made
therein, in the light of the circumstances under which they were made, not
misleading, and the Company will prepare a supplement or amendment to such
prospectus as soon as reasonably practicable thereafter (but in any event
within 30 days) so that, as thereafter delivered to the purchasers of such
Eligible Securities, such prospectus will not contain an untrue 



                                     -5-



statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading;

         (e) make available to Holder (or otherwise provide in accordance with
Section 11(a) of the Act) an earning statement satisfying the provisions of
Section 11(a) of the Act, no later than 45 days after the end of the first
12-month period (or 90 days, if such period is a fiscal year) beginning with
the first month of the Company's first fiscal quarter commencing after the
effective date of such registration statement, which earning statement shall
cover such 12-month period;

         (f) make available for inspection by Holder, any underwriter
participating in any disposition pursuant to such registration statement, and
any attorney, accountant or other agent retained by Holder or any such
underwriter (collectively, the "Inspectors"), all pertinent financial and
other records, pertinent corporate documents and properties and other
pertinent information of the Company (collectively, the "Records") as shall be
reasonably necessary to enable them to exercise their due diligence
responsibility, and cause the Company's officers, directors and employees to
supply all pertinent information reasonably requested by any such Inspector in
connection with such registration statement. Records which the Company
determines, in good faith, to be confidential and which it notifies the
Inspectors are confidential shall not be disclosed by the Inspectors unless
(i) the disclosure of such Records is necessary to avoid or correct a
misstatement or omission in the registration statement, (ii) the release of
such Records is ordered pursuant to a subpoena or other order from a court of
competent jurisdiction, or (iii) the information in such Records has been made
generally available to the public. Holder shall, upon learning that disclosure
of such Records is sought in a court of competent jurisdiction, give notice to
the Company and allow the Company, at the Company's expense, to undertake
appropriate action to prevent disclosure of the Records deemed confidential;

         (g) notwithstanding that the Company may not be or required to remain
subject to the reporting requirements of Section 13 or 15(d) of the Exchange
Act, the Company shall file with the Commission (unless the Commission will
not accept such a filing, in which case the Company shall provide such
documents to Holder) and make available to Holder such annual reports and such
information, documents and other reports as are specified in Sections 13 and
15(d) of the Exchange Act and applicable to a U.S. corporation subject to such
Sections, such information, documents and other reports to be so filed and
provided at the times specified for the filing of such information, documents
and reports under such Sections;

         (h) use commercially reasonable efforts to cause all such Eligible
Securities to be listed on the principal securities exchange on which shares
of the Company's Common Stock are then traded, or such if any, provided that
the applicable listing requirements are satisfied; and

         (i) otherwise comply with all applicable rules and regulations of the
Commission.



                                     -6-



         5.2 Holder shall, upon receipt of any notice from the Company of the
happening of any event of the kind described in Section 5.1(d) hereof,
discontinue disposition of the Eligible Securities pursuant to the
registration statement covering such Eligible Securities until Holder receives
copies of the supplemented or amended prospectus contemplated by Section
5.1(d) hereof, and, if so directed by the Company, Holder will deliver to the
Company (at the Company's expense) all copies, other than permanent file
copies then in Holder's possession, of the prospectus covering such Eligible
Securities current at the time of receipt of such notice. If the Company shall
give any such notice, the Company shall extend the period during which such
registration statement shall be maintained effective pursuant to this
Agreement by the number of days during the period from and excluding the date
of the giving of such notice pursuant to Section 5.1(d) hereof to and
including the date when Holder shall have received the copies of the
supplemented or amended prospectus contemplated by Section 5.1(d) hereof.

         6. REGISTRATION EXPENSES

         6.1 Except as otherwise provided in this Agreement, the Company shall
pay all expenses incurred in complying with Sections 2 and 3 hereof, including
without limitation all registration and filing fees, fees and expenses of
compliance with securities or blue sky laws (including reasonable fees and
disbursements of counsel in connection with blue sky qualifications of the
Eligible Securities), rating agency fees, printing expenses, messenger and
delivery expenses, mailing expenses, internal expenses (including, without
limitation, all salaries and expenses of its officers and employees performing
legal or accounting duties), the fees and expenses incurred in connection with
the listing of the securities to be registered on each securities exchange on
which such securities are required to be listed, fees and disbursements of
counsel for the Company and its independent certified public accountants, the
reasonable fees and disbursements of one counsel of Holder (not to exceed
$20,000), the reasonable fees and expenses of any special experts retained by
the Company in connection with such registration, and fees and expenses of
other persons retained by the Company (all such expenses being herein called
"Registration Expenses"); provided, however, that in connection with the
registration or qualification of the Eligible Securities under state
securities laws, nothing herein shall be deemed to require the Company to make
any payments to third parties in order to obtain "lock-up," escrow or other
extraordinary agreements; and provided further, that all expenses of Holder
other than those expressly assumed by the Company in this Agreement shall be
borne by Holder, including underwriting discounts and commissions, brokerage
commissions, and non-accountable expense allowances attributable to the sale
of Holder's Eligible Securities, and Holder's other out-of-pocket expenses.



                                     -7-



         7. OBLIGATIONS OF THE HOLDER

         7.1 Following the filing of a registration statement registering the
Eligible Securities of Holder and during any period that the registration
statement is effective, Holder shall:

         (a) not effect any stabilization transactions or engage in any
stabilization activity in connection with any securities of the Company in
contravention of Regulation M under the Securities Exchange Act of 1934, as
amended (the "Exchange Act");

         (b) furnish each broker or dealer through whom Holder offers Eligible
Securities such number of copies of the prospectus as the broker may require
and otherwise comply with prospectus delivery requirements under the Act;

         (c) report to the Company each month all sales, pledges and other
dispositions of Eligible Securities made by Holder during said month;

         (d) not, and shall not permit any Affiliated Purchaser (as that term
is defined in Regulation M under the Exchange Act) to, bid for or purchase for
any account in which Holder has a beneficial interest, or attempt to induce
any other person to purchase, any securities of the Company in contravention
of Regulation M under the Exchange Act;

         (e) not offer or agree to pay, directly or indirectly, to anyone any
compensation for soliciting another to purchase, or for purchasing (other than
for Holder's own account), any securities of the Company on a national
securities exchange in contravention of Regulation M under the Exchange Act;

         (f) cooperate in all respects with the Company as it fulfills its
obligations under Sections 2 and 3 of this Agreement;

         (g) furnish such information concerning Holder and the distribution
of the Eligible Securities as the Company may from time to time request;

         (h) sell Eligible Securities only in the manner described in the
Registration Statement; and

         (i) not sell Eligible Securities during any period after the Company
has provided notice to Holder pursuant to Section 5.1(d) above and until the
Company provides to Holder notice that the registration statement no longer
fails to state a material fact required to be stated therein, misstates a
material fact or omits to state a material fact required to be stated therein
or necessary to make the statements made not misleading.



                                     -8-



         8. INDEMNIFICATION; CONTRIBUTION

         8.1 Indemnification by the Company. The Company shall indemnify and
hold harmless, to the fullest extent permitted by law, Holder against all
losses, claims, damages, liabilities and expenses (including reasonable
attorneys' fees) caused by any untrue statement of a material fact contained
in any registration statement, prospectus or preliminary prospectus or any
omission to state therein a material fact required to be stated therein or
necessary to make the statements made therein (in the case of a prospectus, in
the light of the circumstances under which they were made) not misleading,
except insofar as the same are caused by or contained in any information with
respect to Holder furnished to the Company by Holder for use therein or caused
by Holder's failure to deliver a copy of the registration statement or
prospectus or any amendments or supplements thereto in accordance with the
requirements of the Act after the Company has furnished Holder with a copy of
the same.

         8.2 Indemnification by Holder. In connection with any registration
statement in which Holder is participating, Holder will furnish to the Company
in writing such information and affidavits as the Company reasonably requests
for use in connection with any such registration statement or prospectus and
shall indemnify and hold harmless, to the extent permitted by law, the
Company, its directors, each of its officers and each person who controls the
Company (within the meaning of the Act) against any losses, claims, damages,
liabilities and expenses (including reasonable attorneys' fees) resulting from
any untrue statement of a material fact or any omission of a material fact
required to be stated in the registration statement or prospectus or any
amendment thereof or supplement thereto, or necessary to make the statements
therein (in the case of a prospectus, in the light of the circumstances under
which they were made) not misleading, but only to the extent that such untrue
statement or omission is caused by or contained in any information or
affidavit so furnished in writing by Holder, or caused by Holder's failure to
deliver a copy of the prospectus or any amendments or supplements thereto in
accordance with the requirements of the Act after the Company has furnished
Holder with a copy of the same.

         8.3 Conduct of Indemnification Proceedings. Any person entitled to
indemnification hereunder shall give prompt written notice to the indemnifying
party after the receipt by such person of any written notice of the
commencement of any action, suit, proceeding or investigation or threat
thereof made in writing for which such person may claim indemnification or
contribution pursuant to this Agreement and, unless in the reasonable judgment
of such indemnified party a conflict of interest may exist between such
indemnified party and the indemnifying party with respect to such claim,
permit the indemnifying party to assume the defense of such claim with counsel
reasonably satisfactory to such indemnified party. If the indemnifying party
is not entitled to, or elects not to, assume the defense of a claim, it will
not be obligated to pay the fees and expenses of more than one counsel with
respect to such claim. The indemnifying party will not be subject to any
liability for any settlement made without its consent.



                                     -9-



         8.4 Contribution.

         (a) If the indemnification provided for in this Section 8 from the
indemnifying party is unavailable or insufficient to hold harmless an
indemnified party hereunder in respect of any losses, claims, damages,
liabilities or expenses referred to herein, then the indemnifying party, in
lieu of indemnifying such indemnified party, shall contribute to the amount
paid or payable by such indemnified party as a result of such losses, claims,
damages, liabilities or expenses in such proportion as is appropriate to
reflect the relative fault of the indemnifying party and indemnified party in
connection with the actions which resulted in such losses, claims, damages,
liabilities or expenses, as well as any other relevant equitable
considerations; provided, however, that any contribution obligation of Holder
under this Section 8.4 shall be limited to the net proceeds to Holder from the
offering of its Eligible Securities. The relative fault of such indemnifying
party and indemnified party shall be determined by reference to, among other
things, whether any action in question, including any untrue or alleged untrue
statement of a material fact or omission or alleged omission to state a
material fact, has been made by, or relates to information supplied by, such
indemnifying party or indemnified party, and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
action. The amount paid or payable by a party as a result of the losses,
claims, damages, liabilities and expenses referred to above shall be deemed to
include, subject to the limitations set forth in Section 8.3 hereof, any legal
or other fees or expenses reasonably incurred by such party in connection with
any investigation or proceeding.

         (b) The parties hereto agree that it would not be just and equitable
if contribution pursuant to this Section 8.4 were determined by pro rata
allocation or by any other method of allocation which does not take account of
the equitable considerations referred to in the immediately preceding
paragraph.

         (c) If indemnification is available under this Section 8, the
indemnifying party shall indemnify the indemnified party to the full extent
provided in Sections 8.1 and 8.2 hereof without regard to the relative fault
of said indemnifying party or indemnified party or any other equitable
consideration provided for in this Section 8.4.

         9. PARTICIPATION IN UNDERWRITTEN REGISTRATIONS

         9.1 Holder may not participate in any underwritten registration
hereunder unless Holder (a) agrees to sell its securities on the basis
provided to all participants in any underwriting arrangements approved by the
Company and (b) completes and executes all questionnaires, custody agreements,
powers of attorney, indemnities, underwriting agreements and other documents
reasonably required under the terms of such underwriting arrangements.



                                     -10-



         10. MISCELLANEOUS

         10.1 Information Blackout. Upon written notice from the Company to
Holder that the Company has determined in good faith that sale of Eligible
Securities pursuant to the registration statement would require disclosure of
non-public material information not otherwise required to be disclosed under
applicable law, the Company may postpone the filing or effectiveness of any
registration statement hereunder and, if such registration statement has
become effective, the Company shall not be required to maintain the
effectiveness of such registration statement and a Holder shall suspend sales
of Eligible Securities pursuant to such registration statement, in each case,
until such time as the Company notifies the Holder that such information has
been disclosed to the public or that sales pursuant to such registration
statement may otherwise be resumed.

         10.2 Notices. Any notice, request, consent, demand or other
communication required or permitted under this Agreement shall be made in
writing and shall be deemed to have been duly given if (a) mailed by first
class registered or certified mail, return receipt requested, postage prepaid
(and shall be deemed delivered two days after the date received for delivery
by the U.S. Postal Service, whether or not accepted), (b) sent by nationally
recognized next-day delivery courier, charges prepaid (and shall be deemed
delivered one business day after delivery to said courier), or (c) sent by
telefax, telecopier or similar transmission (and shall be deemed delivered on
the date confirmation of the receipt of the transmission is given), if the
appropriate telefax, telecopier or transmission number is included in the
address, addressed to the parties hereto at their respective addresses as
follows:

                           If to the Company:

                           Integra LifeSciences Corporation
                           105 Morgan Lane
                           Plainsboro, NJ  08536
                           Attention:  President
                           Fax:  (609) 799-3297

                           with a copy to:

                           John E. Stoddard III, Esq.
                           Drinker Biddle & Reath LLP
                           105 College Road East
                           Princeton, NJ  08542-0627
                           Fax:  (609) 799-7000

                           If to Holder:

                           GWC Health, Inc.
                           c/o Elan Corporation, plc
                           Lincoln House



                                     -11-



                           Lincoln Place
                           Dublin 2, Ireland
                           Attention:  General Counsel
                           Fax:  353-1-662-4949

                           with a copy to:

                           Cahill Gordon & Reindel
                           80 Pine Street
                           New York, NY 10005
                           Fax:  (212) 269-5420
                           Attention:  William M. Hartnett, Esq.

                           and

                           Athena Neurosciences, Inc.
                           800 Gateway Boulevard
                           South San Francisco, CA 94080
                           Fax:  (650) 875-3620
                           Attention:  General Counsel

         10.3 Arbitration.

         (a) All disputes arising out of or relating to this Agreement which
cannot be settled by the parties shall promptly be submitted to and determined
in arbitration in New York, New York by a panel of three arbitrators (unless
otherwise agreed by the parties), of whom the Holder shall select one, the
Company shall select one and the third shall be selected by the two previously
selected, pursuant to the rules and regulations then obtaining of the American
Arbitration Association; provided that nothing herein shall preclude either
party from seeking, in any court of competent jurisdiction, damages, specific
performance or other equitable remedies in the case of any breach or
threatened breach by the other party of any provision hereof. The decision of
the arbitrators shall be final and binding upon the parties and judgement upon
such decision may be entered in any court of competent jurisdiction.

         (b) Discovery shall be allowed pursuant to the intendment of the
United States Federal Rules of Civil Procedure and as the arbitrators
determine appropriate under the circumstances.

         (c) In any such arbitration proceeding, the prevailing party shall be
entitled to recover reasonable fees and disbursements of counsel in addition
to any other available remedy.

         (d) Such arbitrator shall be required to apply the contractual
provisions hereof in deciding any matter submitted to it and shall not have
any authority, by reason of this 



                                     -12-



Agreement or otherwise, to render a decision that is contrary to the mutual
intent of the parties as set forth in this Agreement.

         10.4 Headings. The headings in this Agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof.

         10.5 Severability. In the event that any one or more of the
provisions contained herein, or the application thereof in any circumstances,
is held invalid, illegal or unenforceable in any respect for any reason, the
validity, legality and enforceability of any such provision in every other
respect and of the remaining provisions contained herein shall not be in any
way impaired thereby.

         10.6 Entire Agreement; Amendments. This Agreement sets forth all the
promises, covenants, agreements, conditions and understandings among the
parties hereto with respect to the subject matter hereof, and supersedes all
prior and contemporaneous agreements, negotiations and understandings,
inducements and conditions, express or implied, oral or written, except as
contained herein. Neither this Agreement nor any provisions hereof may be
modified, amended, waived, discharged or terminated, in whole or in part,
except by a writing signed by all of the parties hereto.

         10.7 Waiver. No waiver by any party hereto of any condition or
release of any term or covenant contained in this Agreement, whether by
conduct or otherwise, in any one or more instances, shall be deemed or
construed as a further or continuing waiver of any such condition or any such
breach or waiver of any other condition.

         10.8 Assignment. Neither party hereto may assign this Agreement to
any person without the prior written consent of the other party hereto; except
that Holder may assign, subject to the provisions of Section 1.3 hereof, this
Agreement to any person to which it sells or otherwise transfers ownership of
any Eligible Securities or Warrants without the prior written consent of the
Company, provided that such person agrees in writing to be bound by the terms
of this Agreement.

         10.9 Binding Nature; Benefit. This Agreement shall be binding upon
and inure to the benefit of the parties hereto and their respective permitted
successors and assigns. Except as otherwise expressly permitted herein, this
Agreement shall not be construed as giving any person, other than the parties
hereto and their respective permitted successors or assigns any legal or
equitable right, remedy or claim under or in respect of this Agreement or any
of the provisions herein contained, this Agreement and all provisions and
conditions hereof being intended to be, and being, for the sole and exclusive
benefit of such parties, and permitted successors or assigns and for the
benefit of no other person or entity.

         10.10 Counterparts. This Agreement may be executed in one or more
counterparts, each of which will be deemed to be an original copy of this
Agreement and all of which, when taken together, will be deemed to constitute
one and the same agreement.



                                     -13-



         10.11 Governing Law. This Agreement and the rights and obligations of
the parties hereunder shall be governed by and construed and interpreted in
accordance with the internal laws of the State of New York applicable to
contracts made and to be performed wholly therein without regard to principles
of conflict of laws.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first written above.

                                            INTEGRA LIFESCIENCES CORPORATION

                                            By:  /s/ Stuart M. Essig
                                                --------------------

                                            GWC HEALTH, INC.

                                            By: /s/ Thomas Lynch
                                                --------------------


                                     -14-




                                                                  Exhibit 10.2



                                     LEASE

                         Net of All Costs and Expenses

         This Lease is made as of the 28th day of September, 1998, between GWC
HEALTH, INC., a New Jersey corporation (the "Landlord"), and RYSTAN COMPANY,
INC., a New Jersey corporation (the "Tenant").

                                W I T N E S S:

         1.   Lease of Premises; Term and 
              Commencement Date

         1.1  The Landlord, for and in consideration of the rents to be paid, 
and of the covenants and agreements hereinafter specified to be kept and
performed, by the Tenant, hereby leases to the Tenant, and the Tenant leases
from the Landlord, the premises located at 47 Center Avenue, Little Falls, New
Jersey (the "Leased Premises"), as more particularly described on Schedule A
annexed hereto. The Leased Premises are leased in "as is" condition except as
provided in this Lease and in the Agreement and Plan of Merger among Integra
LifeSciences Corporation, RC Acquisition Corporation, GWC Health, Inc. and
Rystan Company, Inc. dated the date hereof (the "Merger Agreement").

         1.2  The term of this Lease shall be for three (3) years, effective
September 28, 1998 (the "Commencement Date"), and ending on September 27, 2001
(the "Termination Date"). However, Tenant may terminate this Lease at any time
during the term hereof, without penalty, upon one hundred fifty (150) days
written notice to Landlord, whereupon this Lease shall terminate as if at the
end of the stated term. 

         1.3  This Lease is intended to terminate and replace any existing or
current lease for the Leased Premises. Tenant is hereby released from any claims
related to or arising out 



of any prior lease for the Leased Premises between Landlord and Tenant of any
nature whatsoever. Any reference herein to "this Lease" shall not include any
lease between Landlord and Tenant prior to the date of this Lease.

         2. Annual Rent; Cost of Living 
            Increase; Manner of Payment

         2.1 (a) The Tenant covenants and agrees to pay the Landlord, for the
lease period commencing September 28, 1998 and ending on September 27, 1999, an
annual rental of FIFTY THOUSAND ($50,000) DOLLARS ("Rent").

             (b) The annual rental for each year of the term of this 
Lease, subsequent to the lease period ending September 27, 1999, shall be
determined by multiplying the annual rental then in effect, by a fraction, the
numerator of which is the average of the Revised Consumer Price Index, New York,
New York-Northeastern New Jersey, All Items Index (1967=100) for the last three
months of the lease year then ending, and the denominator of which is the
average of the Revised Consumer Price Index (1967=100) for the last three months
of the preceding year or lease year, as the case may be. In no event, however,
shall the Rent for any lease year be less than $50,000. 2.2 The Rent shall be
due and payable in equal monthly payments, in advance, on the first day of each
month for the term of this Lease.

         3.  Net Lease; Tenant to Pay
             All Costs and Expenses

         3.1 This Lease, and the Rent hereunder, are net of all costs and
expenses appurtenant to the Leased Premises and, the use and operation thereof.
All such costs and expenses, including without limitation, all real estate, use,
sales or other taxes, assessments, 


                                      -2-


utility, service, repair, and other charges, are the sole and exclusive
responsibility of the Tenant; provided, however, that the Landlord shall be
responsible for all costs and expenses incurred in connection with the repair of
all structural damage to the Leased Premises and capital replacement of fixtures
(other than fixtures removable by Tenant in accordance with Section 4.6, if any)
and building systems. Any amount due hereunder shall be immediately remitted
directly to the Landlord upon presentation of a bill therefor, and the Landlord
shall give the Tenant a copy of all said bills, as well as a receipt therefor.
In the event the Landlord shall receive a refund of real estate taxes relating
to the Leased Premises for any year in respect of which the Tenant shall have
made a payment under the provisions of this Section, the proceeds of such refund
shall belong and be paid to the Tenant. Any payments or refunds due hereunder
for any period of less than a full year at the commencement or end of the term
of this Lease shall be equitably prorated between the Landlord and the Tenant to
reflect such event. 

         3.2 The Tenant, at its own cost and expense, has the right in its name
and/or in the Landlord' s name from time to time during the term of this Lease
to take such steps and actions which the Tenant deems proper to effectuate a
reduction of the taxes, assessments, water meter charges or similar items, and
the Landlord agrees, at the sole cost and expense of Tenant, to afford the
Tenant such cooperation as the Tenant may reasonably request with respect to
same. 

         3.3 Landlord shall indemnify and hold Tenant harmless against any and
all claims, losses, liabilities, and damages (including without limitation,
reasonable costs and fees of counsel) incurred under any Environmental Law, in
each case resulting from the presence, use, handling, generation processing,
treatment, storage, transportation, release, discharge or disposal of Hazardous
Materials at, on or beneath the Leased Premises: 

             (i) during the term of this Lease, to the extent caused by the
Landlord, its employees, agents or contractors; and


                                      -3-


             (ii) after the term of this Lease while Landlord or any affiliate 
of Landlord owns the Leased Premises, in each case except to the extent
resulting from or relating to any acts or omissions of Tenant, its employees,
agents and contractors. 

         3.4 Tenant shall indemnify and hold Landlord harmless against any and
all claims, losses, liabilities, and damages (including, without limitation,
reasonable costs and fees of counsel) incurred under any Environmental Law, in
each case resulting from the presence, use, handling, generation, processing,
treatment, storage, transportation, release, discharge or disposal of Hazardous
Materials at, on or beneath the Leased Premises to the extent caused by any
person (except Landlord, its employees, agents or contractors) during the term
of this Lease. 

         3.5 (a) In connection with any transfer, termination or closure of an
industrial establishment at the Leased Premises by the Tenant, including without
limitation termination of this Lease, the Tenant shall comply, at it sole cost
and expense, with the New Jersey Industrial Site Recovery Act ("ISRA"), N.J.S.A.
13:1K-6 et. seq.

             (b)  Tenant shall provide to Landlord all draft submissions 
prepared by it pursuant to ISRA or other Environmental Laws at least five (5)
business days prior to submittal of a final version by Tenant to the New Jersey
Department of Environmental Protection ("NJDEP"). Tenant agrees to consider in
good faith any comments provided by Landlord on any such submission and prior to
making any submission, to make a good faith effort to discuss and resolve any
disagreements with Landlord regarding incorporation of Landlord's comments.
Landlord agrees that Tenant shall be primarily responsible for all
communications with NJDEP and any other governmental agencies related to
compliance by Tenant with ISRA or other Environmental Laws pursuant to this
Lease. It is agreed that, prior to any direct communication by Landlord with
NJDEP or any other governmental agencies concerning Tenant's compliance with
ISRA or other Environmental Laws pursuant to this Lease, Landlord and Tenant
shall each 

                                      -4-


make a good faith effort to discuss and resolve and comments on or
disagreements of Landlord with any of Tenant's submissions to NJDEP or any other
governmental agencies.

             (c) Tenant shall use its best efforts to complete
compliance with ISRA, including without limitation, completing any required
remediation of areas of environmental concern, and obtaining a No Further Action
Letter ("NFA") from NJDEP prior to the termination date of this Lease. In the
event that an NFA has not been obtained by Tenant prior to the termination date
of this Lease, Tenant represents and warrants that it will establish any
Remediation Funding Source required by NJDEP in a form and amount which is in
accordance with the provisions of ISRA.

             (d) Tenant shall use its best efforts to comply with ISRA through 
the use of an Expedited Review Application or its regulatory equivalent pursuant
to ISRA.

             (e) Landlord shall cooperate with Tenant in its efforts to comply 
with ISRA or other Environmental Laws pursuant to this Lease as follows and
agrees: (i) to promptly execute such documents as are reasonably necessary for
compliance by Tenant, provided such documents reflect Tenant's reasonable
request unless prohibited by applicable Environmental Law; (ii) to provide
information upon reasonable notice at reasonable hours which is necessary for
compliance by the Tenant which the Landlord possesses but which the Tenant does
not have available to it, including but not limited to relevant records of
Landlord and access to employees of Landlord reasonably likely to possess
relevant information; and (iii) if and when required by Tenant to comply with
ISRA or other Environmental Laws pursuant to this Lease, upon specific request
of Tenant to provide access to the Leased Premises for the purpose of
investigating, delineating and remediating Hazardous Materials at, on or beneath
the Leased Premises as required for Tenant to comply with ISRA or other
Environmental Law. Such access for Tenant shall be upon terms and conditions
reasonably acceptable to Landlord for the conduct of the 


                                      -5-


specific proposed investigation, delineation and remediation activities required
for compliance by Tenant, provided that any such access and related
investigation, delineation and remediation activities do not interfere
unreasonably with the use and occupancy of the Leased Premises by the Landlord
or any other tenant.

             (f) The Landlord will consider any remedial actions
proposed by Tenant including without limitation remedial actions which involve
Institutional Controls and/or Engineering Controls, but has and reserves the
right, in its sole discretion, to approve and agree to any remedial action
affecting or relating to the Leased Premises.

             (g) Landlord hereby covenants and agrees that during the term of 
this Lease, Landlord shall give Tenant immediate oral and written notice of
Landlord's receipt of any summons, citation, directive, order, claim, letter,
notice or other communication from any governmental authority or other person
alleging any violation of or potential liability under any Environmental Law
with respect to any events, conditions, circumstances, activities, practices or
incidents at or relating to the Leased Premises.

         3.6 Tenant hereby covenants and agrees that during the term of this
Lease, Tenant shall:


                  (i) comply with all Environmental Laws;

                  (ii) give Landlord immediate oral and written notice of any
discharge or release of any Hazardous Materials at, on, under or from the Leased
Premises; and

                  (iii) give Landlord immediate oral and written notice of 
Tenant's receipt of any summons, citation, directive, order, claim, letter,
notice or other communication from any governmental authority or other person
alleging any violation of or potential liability 


                                      -6-


under any Environmental Law with respect to any events, conditions,
circumstances, activities, practices or incidents at or relating to the Leased
Premises.

         3.7 For purposes of Sections 3.3, 3.4, 3.5 and 3.6 above:
"Environmental Law" means the Comprehensive Environmental Response,
Compensation and Liability Act of 1980, as amended, the Resources Conservation
and Recovery Act of 1976, as amended, the New Jersey Industrial Site Recovery
Act, the New Jersey Spill Compensation and Control Act, and any other
applicable federal, state, local, or foreign statute, rule, regulation, order,
decree or judgement relating to pollution or protection of the environment,
including, without limitation, release or threatened release of Hazardous
Material.

         "Engineering Controls" means any physical mechanism to contain or
stabilize contamination or ensure the effectiveness of a remedial action.
Engineering Controls may include, without limitation, caps, covers, dikes,
trenches, leachate collection systems, signs, fences and access controls.

         "Hazardous Material" means any pollutant, contaminate, or hazardous
or toxic waste or substance regulated by any applicable Environmental Law.

         "Institutional Controls" means a mechanism used to limit human
activities at or near a contaminated site, or to ensure the effectiveness of
the remedial action over time, when contaminates remain at a site at levels
above numeric remediation standards which would allow for the unrestricted use
of the property. Institutional Controls may include, without limitation,
structure, land and natural resource use restrictions, well restriction areas,
classification exception areas, deed notices and declarations of environmental
restrictions.


                                      -7-


         4. Use, Maintenance, Alterations, 
            Repairs, Etc.

         4.1 The Tenant may use and occupy the Leased Premises for any lawful
purpose whatsoever, including without limitation, the conduct of its
pharmaceutical business, and the uses normally and customarily incident to the
conduct of such business (such conduct and uses being hereinafter sometimes
referred to as the "Use" or "Uses"). 

         4.2 The Tenant shall not use or occupy the Leased Premises, nor permit
same to be used or occupied, nor do or permit anything to be done in or on the
Leased Premises, in whole or in part, in a manner which would in any way violate
any certificate of occupancy affecting the Leased Premises, or make void or
voidable any insurance then in force with respect thereto, or which may make it
impossible to obtain fire or other insurance required to be furnished by the
Tenant hereunder, or as will cause or be apt to cause structural injury to the
improvements on the Leased Premises or any part thereof, or as will constitute a
public or private nuisance, or which might affect the ability of the Leased
Premises to continue to be used for the nonconforming use now in effect thereon.
Landlord acknowledges and agrees that Tenant's use of the Leased Premises as of
the date hereof does not violate this paragraph. 

         4.3 If, after the date hereof and during the term of this Lease, the
Tenant's use of the Leased Premises shall be changed and as a result thereof
there shall occur a violation of any presently existing laws, regulations,
ordinances or requirements of the federal, state, or municipal governments, or
of any departments, subdivisions, bureaus or offices thereof, or of any other
governmental, public or quasi-public authorities now existing, then the Tenant
shall indemnify and save harmless the Landlord against any recovery or loss to
which the Landlord may be subject or which the Landlord may sustain, including,
without limitation, reasonable attorneys' fees and expenses incurred by the
Landlord, arising from any such violation, provided, however, 


                                      -8-


that the Tenant may, in good faith, upon prior written notice to the Landlord
(and wherever necessary in the name of, but without expense to, the Landlord)
contest the validity of any such laws, regulations, ordinances or requirements
and, pending the determination of such contest may postpone compliance therewith
in such a manner as not to subject the Landlord to a fine or penalty or to
prosecution for a crime, or to cause the Leased Premises or any part thereof to
be condemned. If after the date hereof and during the term of the Lease, any
such laws, regulations, ordinances or requirements shall be modified in any way
so that the use of the Leased Premises, or any part thereof, for the Uses shall
be a violation of any new laws, regulations, ordinances, or requirements of the
federal, state or municipal governments, or of any departments, subdivision,
bureaus or offices thereof, or of any governmental, public or quasi-public
authorities now existing or hereafter created, then the Tenant may in good
faith, upon prior written notice to the Landlord and wherever necessary in the
name of, but without expense to, the Landlord) contest the validity of any such
laws, regulations, ordinances or requirements, or, alternatively, terminate this
Lease in accordance with Section 1.2. 

         4.4 Except as provided in Sections 6 and 7, the Tenant shall keep the
Leased Premises in good condition and shall make all necessary repairs to the
Leased Premises, except for structural repairs or capital replacements of
building systems or fixtures (other than fixtures removable by Tenant in
accordance with Section 4.6) which shall be the responsibility of the Landlord.
The Tenant shall also maintain and keep (but not, unless Tenant causes damage,
have the obligation to replace) the sidewalks and curbs adjacent to the Leased
Premises in good condition, and shall keep such sidewalks free and clear from
rubbish, ice and snow, and shall not encumber or obstruct the same nor allow the
sane to be encumbered or obstructed in any manner. 

         4.5 If the Tenant, being charged with responsibility for any and all
repairs under the terms of this Lease, shall fail to commence same within thirty
(30) days after receipt of 


                                      -9-


notice from Landlord, or after commencing such repair shall fail to complete it
with reasonable diligence, the Landlord may (but shall not be obligated to) make
or complete such repair at the expense of the Tenant.

         4.6 All furniture, furnishings, machines, equipment, and business
fixtures (including by example, water systems) whether or not attached to the
real estate and any other movable property and all installations, additions and
improvements may, at the Tenant' s option, be removed by the Tenant during the
term or upon the expiration or termination of this Lease (provided only that the
removal of same would not cause permanent structural damage to the Leased
Premises). Tenant shall have no obligation to replace equipment, fixtures, etc.
so removed, but shall patch and/or repair any portion of the Leased Premises
damaged by such removal, including without limitation exterior and interior
walls. The Tenant's failure at the expiration or termination of this Lease to
remove any of its property from the Leased Premises shall not be deemed or
construed to constitute the Tenant a holdover tenant. If such removal is not
completed at the expiration or other termination of this Lease, any property
left at the Leased Premises shall become the property of Landlord upon ten (10)
days written notice to Tenant, providing Tenant with the opportunity within said
ten (10) days to remove said property.

         5. Insurance

         5.1 During. the term of this Lease, the Tenant, at its sole cost and
expense, and for the mutual benefit of the Landlord and the Tenant, shall carry
and maintain the following types of insurance in the amounts specified: 

                  (i) Fire and extended coverage insurance covering the Leased
Premises against loss or damage by fire, and against loss or damage by other
risks now or hereafter embraced by the standard extended coverage endorsement
used in New Jersey, in 


                                      -10-


amounts sufficient to prevent the Landlord or the Tenant from becoming a
co-insurer under the terms of the applicable policies.

                  (ii) Comprehensive public liability insurance, including
property damage, insuring the Landlord and the Tenant against liability for
injury to persons or property occurring in or about the Leased Premises, or
arising out of the ownership, maintenance, use or occupancy thereof. The
liability under such insurance shall not be less than $500,000 for any one
person injured or killed, and not less than $1,000,000 for any one accident and
not less than $300,000 for personal property damage for any one accident. 

         5.2 All policies of insurance (except liability insurance) shall
provide by endorsement that any loss shall by payable to the Landlord or the
Tenant as their respective interests may appear. The Tenant shall have the
privilege of procuring and obtaining all of such insurance through its own
sources. 

         5.3 Within 30 days of the execution of this Lease and thereafter by the
30th day of June of each year of the term of this Lease, the Tenant shall
deliver to the Landlord evidence of the above-mentioned insurance coverage
satisfactory to counsel for the Landlord. Upon the Tenant's failure to comply in
full with this Section 5, the Landlord shall have the immediate right to obtain
the aforesaid insurance coverage, to pay the premiums therefor, and to add said
premises to the monthly installment of rent next due, which amount shall be paid
by the Tenant to the Landlord in addition to said monthly installment. 

         5.4 Neither the Tenant nor the Landlord, nor their respective agents or
employees, shall be liable to the other for loss or damage covered by any
insurance policy.


                                      -11-


         6. Damage or Destruction

         6.1 If the Leased Premises or any part thereof are so damaged by fire
or other casualty as to render the Leased Premises unsuitable, in the Tenant's
reasonable judgment, for the reasonable conduct of the Tenant's business, the
Tenant shall have the option, exercisable within thirty (30) days after the date
of such casualty, to cancel and terminate this Lease.

         6.2 If the Leased Premises or any part thereof shall be partially
damaged by fire or other casualty, and such damage in the Tenant's reasonable
judgment does not render the Leased Premises unsuitable for the reasonable
conduct of the Tenant's business, the Landlord shall promptly apply any
insurance proceeds to repair and restore the Leased Premises in a manner, and to
the extent possible, corresponding to the condition of such property immediately
prior to such occurrence, provided that the Landlord shall not be required to
expend any amount on such repairs and restoration in excess of the amount the
insurance proceeds received by it on account of such fire or other casualty,
and, provided further, that if such insurance proceeds are insufficient to
enable the Landlord to comply with its obligations hereunder, the Landlord shall
have the option, exercisable within ninety (90) days after the date of such
casualty, to cancel and terminate this Lease. Until such repairs and restoration
shall have been completed, the rent and real estate taxes payable by the Tenant
hereunder shall be apportioned and abated according to the part of the Leased
Premises which is unsuitable for the reasonable conduct of the Tenant's
business. 

         6.3 In the event that this Lease is terminated pursuant to Section 6.1,
the rent and real estate taxes for the calendar month in which such damage
occurs shall be apportioned as of the date on which such damage first occurred,
and if the Tenant shall have paid the rent and/or real estate taxes due
hereunder in advance of that date, the Landlord shall forthwith refund to the
Tenant so much of such rent and/or real estate taxes as may be due the Tenant as
a result of such 


                                      -12-


apportionment. If the Tenant shall not have so paid, the Tenant shall be
responsible in full for those days prior to the damage, and proportionately
thereafter. The Tenant shall not be liable for any rent or real estate taxes
subsequent to such date. 

         6.4 Any insurance proceeds from any insurance policy maintained in 
order to keep the Tenant in compliance with Section 5 hereof which are received
by the Tenant on account of any damage to or destruction of the Leased Premises,
or any part thereof, which is covered by the provisions of this Section 6 shall
be paid immediately to the Landlord.

         7. Condemnation, Taking by Eminent Domain

         7.1 If (a) all or any part of the Leased Premises shall be acquired or
condemned by eminent domain by any competent governmental authority and the part
not so taken, in the Tenant's reasonable judgment, shall not be suitable for the
reasonable conduct of the Tenant's business, or (b) access to the Leased
Premises is so taken and such taking, the Tenant's reasonable judgement, renders
the Leased Premises unsuitable for the reasonable conduct of the Tenant's
business, then, in either of such events, the term of this Lease shall cease and
terminate on the date of the vesting of title in the governmental authority. If
less than all of the Leased Premises is so taken, and this Lease terminates
pursuant to the foregoing, the Tenant shall nevertheless have the right, but not
the obligation, to remain in possession of the remainder of the Leased Premises
for an additional period not to exceed twelve (12) months after the date of the
vesting of title as aforesaid; provided, however, that in no event shall such
additional period extend beyond the Termination Date. The Tenant may so elect by
notice to the Landlord given within sixty (60) days after the Tenant is notified
of the vesting of title, specifying the desired additional period, in which
latter event this Lease shall end on the date so specified by the Tenant. The
rent and real estate taxes due hereunder for that part of the Leased Premises
not 


                                      -13-


condemned and for such additional period shall be abated and apportioned to
account for the part of the Leased Premises which was taken or rendered
unsuitable for the reasonable conduct of the Tenant's business. The rent and
real estate taxes due hereunder for the month in which such termination takes
place shall be apportioned as of the date of termination. If the Tenant shall
have paid such rent and/or real estate taxes in advance of that date, the
Landlord shall forthwith refund to the Tenant so much of such rent and/or real
estate taxes as is due the Tenant by reason of such apportionment. If the Tenant
shall not have so paid, the Tenant shall be liable in full for all days prior to
the taking, and proportionately thereafter. 

         7.2 If part, but not all of the Leased Premises shall be acquired or
condemned by eminent domain by any competent governmental authority and the part
not so taken in the Tenant's reasonable judgment shall be sufficient and
suitable for the reasonable conduct of the Tenant's business, this Lease and the
term thereof shall not cease and terminate, but the Tenant shall be entitled to
a reduction in the rent and real estate taxes to be paid by it hereunder from
and after the date of the vesting of title, in such amount as may be mutually
agreed upon by the Landlord and the Tenant within a period of thirty (30) days
subsequent to the date of the vesting or failing such agreement, in such amount
as shall be fixed by appraisal as hereinafter provided in Section 8. 

         7.3 As soon after the date of the vesting as possible the Landlord
shall restore the portion of the Leased Premises not acquired or condemned by
eminent domain, in the manner and to the extent possible, to the condition that
such portion of the Leased Premises was in immediately prior thereto. The
Landlord shall not be required to spend more on such restoration that the amount
it received in the award. 

         7.4 Promptly upon receipt of any notice of a proposed taking, notice of
application to condemn, notice to file claims, notice of the vesting of title in
the condemning 


                                      -14-


authority, and/or any other notice received by the Landlord, or otherwise coming
to the Landlord's attention, in connection with any taking or condemnation, the
Landlord shall send to the Tenant copies of such notices in the manner
prescribed herein for the giving of notices. 

         7.5 If there shall be included in the award made to the Landlord any
amount attributable to the cost of the Tenant's moving and relocation expenses,
the Landlord shall, within five (5) days after the receipt thereof by the
Landlord, pay to the Tenant the portion of the award so attributable. Except for
its right to compensation for moving and relocation expenses, Tenant waives all
rights to participate in, or receive amounts paid pursuant to, such award.

         8. Appraisal

         In the event that it shall be necessary to appraise the abatement
and/or reduction of the rent and/or the real estate taxes payable hereunder by
the Tenant pursuant to any Section of this Lease, each party agrees to appoint a
qualified, unbiased person within fifteen (15) days after notice in writing of
the necessity for appraisal, and to advise the other party of its choice. On the
failure to either party to appoint an appraiser within said fifteen (15) day
period, the person appointed as appraiser by the other party may appoint an
appraiser to represent the party in default. The two appraisers shall appraise
the abatement and/or reduction of such rent and/or such real estate taxes and/or
such purchase price of the Leased Premises, as the case may be. In the event of
their inability to reach a result within thirty (30) days after the appointment
of the second appraiser, they shall appoint a third qualified and responsible
appraiser. In the event the two appraisers are unable to agree on such third
appraiser, such appraisers shall ask the then President of the New Jersey Bar
Association to appoint him. The appraisers shall each be real estate brokers who
shall have had at least fifteen (15) years of experience in the business of
appraising real estate or acting as brokers of real estate in Newark, New
Jersey. Each party 


                                      -15-


agrees to pay one-half (1/2) of the expenses and reasonable fees of he
appraisers, and to be bound by the decision of a majority of them.

         9. Assignment, Subletting

         9.1 The Tenant shall not sublet the Leased Premises or any portion
thereof, or assign this Lease, without the prior written consent of the Landlord
in each instance, which consent the Landlord covenants not to withhold or delay
unreasonably. The Landlord's consent shall not be required with respect to an
assignment of this Lease or a subletting of the Leased Premises or any part
thereof to a corporation controlling, controlled by, or under common control
with the Tenant, or to any successor of the Tenant by way of consolidation or
merger. 

         9.2 If this Lease be assigned, whether or not in violation of the
provisions of this Lease, the Landlord may, and is hereby empowered to, collect
rent from the assignee. In such event, the Landlord may apply the net amount
received by it to the rental and other payments herein reserved or provided for,
and no such collection shall be deemed a waiver of the covenant herein against
assignment, mortgage, encumbrance, pledge of subletting, or an acceptance of the
assignee or sub-tenant as a tenant under this Lease, or a release of the Tenant
from the further performance of the covenants herein contained on the part of
the Tenants. 

         9.3 The making of any assignment, mortgage, pledge, encumbrance or
subletting, in whole or in part, whether or not with the consent of the
Landlord, shall not operate to relieve the Tenant from its obligations under
this Lease and, notwithstanding any such assignment, mortgage, pledge,
encumbrance or subletting, the Tenant shall remain liable for the payment of the
rental and other charges, and for the due performance of all the covenants,
agreements, terms and provisions contained in this Lease, for the term of this
Lease, whether or 


                                      -16-


not there shall have been any prior termination of this Lease by summary
proceedings or otherwise.

         10. Default Provisions

         10.1 This Lease and the term and estate hereby granted are subject to
the limitation that: 

              (a) whenever the Tenant shall default in the payment of any 
installment of rent or of any other sum payable by the Tenant to the Landlord on
any day upon which the same is due, and if such default shall continue for ten
(10) days after the date thereof; or

              (b) whenever the Tenant shall do or permit to be done, whether by
action or inaction, anything contrary to any covenant or agreement on the part
of the Tenant herein contained, or contrary to any of the covenants, agreements,
terms and provisions of this Lease, or shall fail to keep or perform any of the
covenants, agreements, terms or provisions contained in this Lease which, on the
part or behalf of the Tenant, are to be kept or performed (other than those
referred to in the foregoing subsection (a) of this Section), and the Tenant
shall fail to commence to take steps to remedy the same within fifteen (15) days
after the Landlord shall have given to the Tenant a written notice specifying
the same, or having so commenced shall thereafter fail to proceed diligently to
remedy the same; or 

              (c) whenever an involuntary petition shall be filed against the 
Tenant under any bankruptcy or insolvency law or under the reorganization
provisions of any law or like import, or a receiver of the Tenant or of or for
the property of the Tenant shall be appointed without the acquiescence of the
Tenant, or whenever this Lease or the estate hereby granted or the unexpired
balance of the term would, by operation of law or otherwise, except for this


                                      -17-


provision, devolve upon or pass to any person, firm or corporation other than
the Tenant, and such situation under this subsection (c) shall continue and
shall remain undischarged or unstayed for an aggregate period of sixty (60) days
(whether or not consecutive) or shall not be remedied by the Tenant within sixty
(60) days; or 

              (d) whenever the Tenant shall make an assignment of its property 
for the benefit of creditors or shall file a voluntary petition under any
bankruptcy or insolvency law, or whenever any court of competent jurisdiction
shall approve a petition filed by the Tenant under the reorganization provisions
of the United States Bankruptcy Act or under the provisions of any law of like
import, or whenever the Tenant shall desert or abandon the Leased Premises; then
regardless of and notwithstanding the fact that the Landlord has or may have
some other remedy under this Lease or by virtue hereof, in law or in equity, the
Landlord may give to the Tenant notice of intention to end the term of this
Lease by specifying a day not less than five (5) days thereafter, and upon the
giving of such notice, this Lease and the term and estate hereby granted shall
expire and terminate upon the day so specified and all rights of the Tenant
under this Lease shall expire and terminate, but the Tenant shall remain liable
for damages as hereinafter provided. 

         10.2 Upon any such termination or expiration of this Lease, the Tenant
shall peaceably quit and surrender the Leased Premises to the Landlord, in broom
clean condition and in good repair, and the Landlord may without further notice
enter upon, re-enter, possess and repossess itself thereof, by summary
proceedings, ejectment or otherwise, and may have, hold, and enjoy the Leased
Premises and the right to receive all rental and other income of and from the
same. 

         10.3 It is covenanted and agreed by the Tenant that in the event of the
expiration or termination of this Lease or re-entry by the Landlord, under any
of the provisions of 


                                      -18-


this Section 10 or pursuant to law, by reason of default hereunder on the part
of the Tenant, the Tenant will pay to the Landlord the damages, incurred by the
Landlord as a result of such early termination and that the Landlord will have
all rights and remedies provided by law in such event. Landlord shall make
reasonable efforts to mitigate damages. In this circumstance, "reasonable
efforts" means that the Landlord will offer the Premises for Lease and will list
the Property with a broker, cause reasonable publication of the availability of
the Premises for lease and cause the Premises to be available for inspection by
prospective Tenants. Landlord shall not be liable and Tenant's responsibility
hereunder shall not be diminished if Landlord fails to lease the premises
despite such reasonable efforts. 

         10.4 The Tenant, for itself, its successors, assigns and any and all
persons claiming through or under the Tenant, including creditors of all kinds,
does hereby waive and surrender all right and privilege which it might have
under or by reason of any present or future law, to redeem the Leased Premises,
or to have a continuance of this Lease for the term hereof after being
dispossessed or ejected therefrom by process of law or after the termination of
this Lease as herein provided.

         11. Landlord' s Right to Perform; Cumulative
             Remedies; Waivers, Attorney's Fees

         11.1 If the Tenant shall fail to pay any taxes or make any other
payment required to be made under this Lease or shall default in the performance
of any other covenant, agreement, term, provisions or condition herein
contained, the Landlord, without being under any obligation to do so, and
without thereby waiving such default, may make such payment and/or remedy such
other default for the account and at the expense of the Tenant and, immediately
and without notice in the case of emergency, or in any other case only provided
the Tenant shall fail 


                                      -19-


to make such payment or remedy such default with all reasonable dispatch after
the Landlord shall have notified the Tenant in writing of such default.

         11.2 The Landlord may by due process restrain any breach or threatened
breach of any covenant, agreement, term, provision or condition herein
contained, but the mention herein of any particular remedy shall not preclude
the Landlord from any other remedy it might have, either in law or in equity.
The failure of the Landlord to insist upon the strict performance of any one of
the covenants, agreements, terms, provisions or conditions of this Lease or to
exercise any right, remedy or election herein contained or permitted by law
shall not constitute or be construed as a waiver or relinquishment for the
future of such covenant, agreement, term, provision, condition, right, remedy or
election, but the same shall continue and remain in full force and effect. Any
rights or remedies of the Landlord specified in this Lease, or any other right
or remedy that the Landlord may have at law, in equity or otherwise upon breach
by the Tenant of any covenant, agreement, term, provision or condition contained
in this Lease, shall be distinct, separate and cumulative rights or remedies,
and no one of them, whether exercised by the Landlord or not, shall be deemed to
be in exclusion of any other. No covenant, agreement, term, provision or
condition of this Lease shall be deemed to have been waived by the Landlord
unless such waiver be in writing, signed by the Landlord or the Landlord's agent
who shall have been duly authorized as such in writing by the Landlord. Receipt
or acceptance of rent by the Landlord shall not be deemed to be a waiver of any
default under the covenants, agreements, terms, provisions and conditions of
this Lease, or of any right which the Landlord may be entitled to exercise under
this Lease. 

         11.3 In the event of any default by the Tenant under this Lease, the
Landlord shall be entitled, in addition to any other rights and remedies
hereunder, to the reimbursement by 


                                      -20-


the Tenant of reasonable attorneys' fees incurred by the Landlord in the
exercise of its rights and remedies.

         12. Quiet Enjoyment; Transfer
             of Landlord's Interest

         12.1 The Landlord covenants that if and so long as the Tenant keeps and
performs each and every covenant, agreement, term, provision and condition
herein required to be kept and performed on the part and behalf of the Tenant,
the Tenant shall peacefully and quietly enjoy the Leased Premises without
hindrance or molestation by the Landlord, subject to the covenants agreements,
terms, provisions and conditions of this Lease. 12.2 It is expressly understood
and agreed that the term "Landlord", as used in this Lease, means only the
present and undersigned owner of the Leased Premises, and in the event of the
sale, assignment or transfer by such owner of its interest in all or part of
said Leased Premises, such owner shall thereupon be released and discharged from
all covenants and obligations of the Landlord thereafter accruing with respect
to the portion of the Leased Premises so transferred. However, such covenants
and obligations shall be binding upon each new owner for the time being of the
Leased Premises or any part thereof.

         13. Landlord's Right to Enter

         The Landlord may enter upon the Leased Premises, or any part thereof,
for the purpose of ascertaining the condition of said Leased Premises, or
determining whether the Tenant is observing and performing the obligations
assumed by it under this Lease, all without hindrance or molestation from the
Tenant. Such rights of entry shall be exercisable at reasonable time, at
reasonable hours, and on reasonable notice.


                                      -21-


         14. Subordination; No Further Encumbrances

         14.1 This Lease shall not be a lien against the Leased Premises in
respect of any mortgages that presently exist upon the Leased Premises. 

         14.2 This Lease shall be subject and subordinate to any mortgage which
may hereafter be placed upon the Leased Premises, or to any renewals,
extensions, modifications, consolidations or replacements thereof or of
presently existing mortgages, and Tenant shall, within ten (10) days of
Landlord's request, execute and deliver a document evidencing the subordination
of this Lease and Tenant's agreement to attorn as set forth below provided that
simultaneously with the execution thereof the holder of said mortgage and/or
mortgages shall deliver an instrument to the Tenant duly executed for recording,
stating that the possession and enjoyment of the Leased Premises by the Tenant
shall in no way be disturbed by reason of any foreclosure or other proceedings
that may be taken with respect to any such mortgage or the indebtedness which it
may secure, so long as the Tenant complies with the terms, covenants and
conditions of this Lease, or any renewals thereof, and the Tenant covenants to
execute, promptly without cost to it whenever required by the Landlord, any
certificate the Landlord may request in accordance with the provisions of this
Section. If the interest of the Landlord in the Leased Premises is transferred
to any person ("Purchaser") pursuant to or in lieu of proceedings for
enforcement of any encumbrance, Tenant shall immediately and automatically
attorn to the Purchaser, and this Lease shall continue in full force and effect
as a direct lease between the Purchaser and the Tenant on the terms and
conditions set forth herein.


                                      -22-


         15. Indemnification

         15.1 Except as provided in Section 3.3 hereof, the Landlord and the
holders of any now existing or hereafter executed mortgage of the Landlord's
interest in the Leased Premises (the "Superior Interests") shall not be liable
to the Tenant and the Tenant hereby waives all claims against such parties for
any loss, injury or other damage to person or property in or about the Leased
Premises from any cause whatsoever, including, without limitation, water leakage
of any character from the roof, walls, basement or other portion of the Leased
Premises, or gas, fire, explosion or other electricity within the Leased
Premises; provided, however, that the foregoing waiver shall be inapplicable to
any loss, injury or damage resulting directly from the Landlord's or its
authorized representatives' negligence or willful misconduct or the breach of
this Lease by the Landlord. 

         15.2 The Tenant shall hold Landlord and the holders of any Superior
Interest, and the constituent shareholders, partners or other owners thereof,
and all of their agents, contractors, servants, officers, directors, employees
and licensees (collectively, the "Indemnitees") harmless from and indemnify the
Indemnitees against any claims, liability, damages, costs or expenses,
including, without limitation, reasonable attorney's fees and costs incurred in
defending against the same ("Claims"), to the extent arising from (i) the acts,
omissions, negligence or willful misconduct of the Tenant, the Tenant's
employees, agents, contractors, licensees, subtenants, customers, guests or
invitees in or about the Leased Premises during the term of this Lease, (ii) any
construction or other work undertaken by the Tenant on the Leased Premises
during the term of this Lease, (iii) any breach or Event of Default under this
Lease by the Tenant or (iv) any accident, injury or damage, howsoever and by
whomsoever caused, to any person or property, occurring in or about the Leased
Premises during the term of this Lease; except for such Claims to the extent
they are caused directly by the negligence or 


                                      -23-


willful acts or omissions of the Landlord or its authorized representatives. In
case any action or proceeding be brought against any of the Indemnities by
reason of any such Claim, the Tenant, upon notice from the Landlord, covenants
to resist and defend at the Tenant's sole expense such action or proceeding by
counsel reasonably satisfactory to the Landlord. The provisions of this
Paragraph 15.2 shall survive the expiration or other termination of this Lease
with respect to any injury, illness, death or damage occurring prior to such
expiration or other termination. 15.3 The Landlord shall hold the Tenant and the
Tenant's shareholders, officers, distributors, partners, agents, contractors,
servants, licensees, subtenants and employees ("Tenant's Indemnitees") harmless
from and indemnify the Tenant and the Tenant's Indemnities against any and all
Claims incurred in connection with or arising from any injury, illness, or death
to any person or damage to any property or from any other cause whatsoever
occurring in, on or about any part of the Leased Premises when such injury,
illness, death or damage shall be caused by the breach under this Lease by the
Landlord or by the acts, omissions, negligence or willful misconduct of the
Landlord, its agents, contractors, partners, servants, officers, directors,
licensees or employees, except to the extent caused by the negligence or
misconduct of Tenant's Indemnitees. The provisions of this Paragraph 

         15.3 shall survive the expiration or other termination of this Lease
with respect to any injury, illness, death or damage occurring prior to such
expiration or other termination. In case any action or proceeding be brought
against the Tenant or Tenant's Indemnitees by reason of any such Claim, the
Landlord, upon notice from the Tenant, covenants to resist and defend at the
Landlord's sole expense such action or proceeding by counsel reasonably
satisfactory to the Tenant. Notwithstanding anything to the contrary set forth
in this Paragraph 15.3 or elsewhere in this Lease, in no event shall the
Landlord be liable for any consequential or remote damages, or for loss of or
damage to artwork, currency, jewelry, bullion, securities or other property in
the Leased Premises, not in the nature of ordinary fixtures, 


                                      -24-


furnishings, equipment and other property used in general business office
activities and functions. 

         16. Holding Over

         If the Tenant remains in possession of the Leased Premises after the
expiration or other termination of this Lease with the express written consent
of the Landlord, the Tenant's occupancy shall be a month-to-month tenancy at a
rent agreed upon by the Landlord and the Tenant, but in no event less than the
Rent payable under this Lease during the last full month prior to the date of
the expiration or other termination of this Lease. Except as provided in the
preceding sentence, the month-to-month tenancy shall be on the terms and
conditions of this Lease. The Landlord's acceptance of Rent after such holding
over with the Landlord's written consent shall not result in any other tenancy
or in a renewal of the term hereof. If the Tenant remains in possession of the
Leased Premises after the expiration of the termination of this Lease without
the Landlord's written consent, the Tenant's continued possession shall be on
the basis of a tenancy at sufferance and Tenant shall pay Rent during the
holdover period an amount equal to the greater of (i) one hundred fifty percent
(150%) of the fair market rental (as reasonably determined by Landlord) for the
Leased Premises or (ii) two hundred percent (200%) of the Rent payable under
this Lease for the last full month prior to the date of such expiration or other
termination.

         Tenant shall indemnify and hold Landlord harmless from and against
all damages, costs or expenses, including, without limitation, reasonable
attorneys fees and costs of re-renting, if required, incurred by Landlord
resulting from Tenant's failure to surrender the Leased Premises within the
time provided under this Lease, for any (i) rent payable by any prospective
tenant of the Leased Premises or any portion thereof and (ii) Landlord's
damages as result of such prospective tenant rescinding the prospective lease
of the Leased Premises or any portion thereof 


                                      -25-


by reason of such failure to timely surrender the Leased Premises; provided that
Landlord shall make reasonable efforts, as defined in Paragraph 10.3, above, to
mitigate damages.

         All indemnification obligations, including without limitation those
contained in Paragraphs 3.3 and 3.4, provided for in this Lease shall continue
and remain in full force and effect during any holdover period, and resulting
month to month tenancy.

         17. Estoppel Certificates

         At any time and from time to time, upon not less than ten (10) days'
prior notice from the Landlord, the Tenant shall execute, acknowledge and
deliver to the Landlord a statement certifying the commencement date of this
Lease, stating that this Lease is unmodified and in full force and effect (or if
there have been modifications, that this Lease is in full force and effect as
modified and the date and nature of each such modification), that the Landlord
is not known to be in default under this Lease (or, if the Landlord is in
default, specifying the nature of such default), that the Tenant is not known to
be in default under this Lease (or, if the Tenant is in default, specifying the
nature of such default), the current amounts of and the dates to which Rent has
been paid, and setting forth such other matters as may be reasonably requested
by the Landlord. Any such statement may be conclusively relied upon by a
prospective purchaser of the Leased Premises or by a lender obtaining a lien on
the Leased Premises as security.

         18. Late Charge

         The Tenant acknowledges that late payment of any installment of Rent
will cause the Landlord to incur costs not contemplated by this Lease and that
the exact amount of such 


                                      -26-


costs would be extremely difficult and impracticable to fix. Such costs include,
without limitation, processing and accounting charges, late charges that may be
imposed on the Landlord by the terms of any encumbrance or note secured by the
Leased Premises and the loss of the use of the delinquent funds. Therefore, if
any installment of Rent is not received within ten (10) days of the date due,
the Tenant shall pay to the Landlord on demand an additional sum of four (4%) of
the overdue installment, which sum represents a fair and reasonable estimate of
the costs that the Landlord will incur by reason of late payment by the Tenant.
Acceptance of any late charge shall not constitute a waiver of the Tenant's
default with respect to the overdue amount, nor prevent the Landlord from
exercising any of the other rights and remedies available to the Landlord.

         19. Attorneys' Fees

         In the event of any action or proceeding between the Landlord and the
Tenant (including an action or proceeding between the Landlord and the trustee
or debtor in possession while Tenant is a debtor in a proceeding under any
bankruptcy law) to enforce any provision of this Lease, the losing party shall
pay to the prevailing party all costs and expenses, including, without
limitation, reasonable attorneys' fees and expenses, incurred in such action and
in any appeal in connection therewith by such prevailing party. The "prevailing
party" will be determined by the court before whom the action was brought based
upon an assessment of which party's major arguments or positions taken in the
suit or proceeding could fairly be said to have prevailed over the other party's
arguments or positions on major disputed issues in the court's decision.


                                      -27-


         20. Real Estate Brokers

The Landlord and the Tenant each represents and warrants to the other that
neither party has authorized or employed, or acted by implication to authorize
or to employ, any real estate broker or salesman to act for such party in
connection with this Lease. Each party shall hold the other harmless from and
indemnify and defend the other against any and all claims by any real estate
broker or salesman for a commission, finder's fee or other compensation as a
result of the inaccuracy of such party's representation above.

         21. Authority

         If the Tenant is a corporation, partnership, trust, association or
other entity, the Tenant and each person executing this Lease on behalf of the
Tenant, hereby covenants and warrants that (i) the Tenant is duly incorporated
or otherwise established or formed and validly existing under the laws of its
state of incorporation, establishment or formation, (ii) the Tenant has and is
duly qualified to do business in New Jersey, (iii) the Tenant has full
corporate, partnership, trust, association or other appropriate power and
authority to enter into this Lease and to perform all the Tenant's obligations
hereunder and (iv) each person (and all of the persons if more and one signs)
signing this Lease on behalf of Tenant is duly and validly authorized to do so.

         22. Compliance with Law.

         Tenant shall not do or permit anything to be done in or about he Leased
Premises which will in any way conflict with any law, ordinance or governmental
requirement now in force or which may hereafter be enacted. Tenant, at it sole
cost and expense, shall promptly comply with all such laws, ordinances and
governmental requirements and with the requirements 


                                      -28-


of any board of fire underwriters or other similar body now or hereafter
constituted relating to the condition, use or occupancy of the Leased Premises.
The judgment of any court of competent jurisdiction or the admission of Tenant
in an action against Tenant, whether or not Landlord is a party thereto, that
Tenant has violated any law, ordinance or governmental requirement shall be
conclusive of that fact as between Landlord and Tenant. Tenant shall immediately
furnish Landlord with any notices received from any insurance company or
governmental agency or inspection bureau regarding any unsafe or unlawful
condition within the Leased Premises. Notwithstanding the foregoing, Tenant need
not comply with any such laws, ordinances, orders, rules, regulations or
requirements during any period that Tenant is contesting the validity or
applicability thereof in accordance with the terms of this paragraph. Tenant may
contest and appeal any such law, ordinance, orders, rules, regulations or
requirements provided that the same are prosecuted diligently and in good faith
and provided that the same shall not subject Landlord to any fines or penalties
or to prosecution for a criminal or civil offense, or constitute a default under
any lease, contract or mortgage under which Landlord maybe obligated, or cause
the Leased Premise or any part thereof to be condemned or vacated.

         23. Notices

         All notices, demands, requests or other communication which may be or
are required to be given, served or sent by one part to the other shall be in
writing, and shall be deemed to have been given properly if mailed by registered
or certified mail to the address of such party set forth below, or to such
address as such party shall notify the other in like manner:


                                      -29-


                  If to Landlord:
                                    GWC Health, Inc.
                                    c/o Elan Corporation, plc
                                    Lincoln House
                                    Lincoln Place
                                    Dublin 2, IRELAND
                                    Telecopy:  353-1-662-4960
                                    Attention:  General Counsel

                             with a copy to:

                                    Cahill Gordon & Reindel
                                    80 Pine Street
                                    New York, New York  10005
                                    Telecopy:  (212) 269-5420
                                    Attention:  William M. Hartnett

                                    and

                                    Athena Neurosciences, Inc.
                                    800 Gateway Boulevard
                                    South San Francisco, California   94080
                                    Telecopy:  (650) 875-3620
                                    Attention:  General Counsel

                  If to Tenant:

                                    Rystan Company, Inc.
                                    c/o Integra LifeSciences Corporation
                                    105 Morgan Lane
                                    Plainsboro, New Jersey  08536
                                    Telecopy:  (609) 799-3297
                                    Attention:  President

                             with a copy to:

                                    Drinker Biddle & Reath
                                    105 College Road East
                                    Princeton, New Jersey  08542
                                    Telecopy:   (609) 799-7000
                                    Attention:  John E. Stoddard, III, Esq.


                                      -30-


         24. Governing Law

         The Lease shall be governed by and construed and enforced in accordance
with the laws of the State of New Jersey.

         25. Entire Agreement

         This Lease, together with the relevant provisions of any other document
referred to herein between the parties hereto, constitutes the entire agreement
between the parties hereto with respect to the subject matter hereof.

         IN WITNESS WHEREOF, the parties have caused these presents to be signed
by their proper and duly authorized corporate officers and their corporate seal
to be hereto affixed, this 28th day of September, 1998.

ATTEST:                                     GWC HEALTH, INC., Landlord

______________________________              By: /s/ Edmond Bergeron

                                            Title: President


ATTEST:                                     RYSTAN COMPANY, INC., Tenant

______________________________              By: /s/ David B. Holtz

                                            Title: Treasurer


                                      -31-